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ABSTRACT 
Autosomal recessive polycystic kidney disease (ARPKD) is a rare genetic 
disorder that occurs in 1:20,000 live births. Patients present with a broad spectrum of 
symptoms involving the kidneys, liver, and pancreas. Renal manifestations are 
characterized by the presence of cysts that are derived from dilated collecting ducts. All 
patients with ARPKD develop some degree of congenital hepatic fibrosis (CHF) at birth. 
CHF is characterized by bile duct dilation resulting in eventual development of cysts and 
pericystic fibrosis in the liver. Accompanying cyst growth and fibrosis, recent reports 
suggest that inflammation is also present, and likely contributes to disease 
pathogenesis and/or progression. Therefore, three interrelated processes form a 
‘pathogenic triumvirate’ in CHF/ARPKD: cell proliferation (cyst growth), fibrosis, and 
inflammation. Aside from management of symptoms, and liver and/or kidney transplant, 
no effective pharmacologic therapies exist for CHF/ARPKD. Therefore, the goal of this 
research was to explore additional mechanisms of hepatic cyst and pericystic fibrosis 
progression in CHF/ARPKD to identify new points of therapeutic intervention.  
We first characterized the gene expression in CHF/ARPKD by performing RNA-
seq in whole liver from Sprague Dawley (SD) and PCK rats at postnatal day (PND) 15, 
20, 30, and 90. Upstream regulator and pathway analysis of differentially expressed 
genes was subsequently conducted using Ingenuity Pathways Analysis (IPA). We found 
the number of differentially expressed genes was increased in PCK rats over time. 
Among the top genes upregulated in PCK rats, Cd44, the most well-described receptor 
for the extracellular matrix glycosaminoglycan hyaluronan, and Tead4, a transcription 
factor required for regulation of genes downstream of the Hippo-kinase- yes-associated 
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protein pathway, were consistently upregulated from PND 15 to PND 90. This led us to 
investigate the role of hyaluronan and yes associate protein (YAP) in CHD/ARPKD.  
Upstream regulator analysis predicted activation of several pro-proliferative and 
pro-inflammatory transcription factors in PCK rats including Ctnnb (catenin beta-1), 
Mtpn (myotrophin), Tcf7l2 (transcription factor 7 like 2), and several Stat (signal 
transducer and activator of transcription) family members (z score ≥ 2). Further, PCK rat 
livers exhibited inhibition of Smad7, an inhibitory SMAD, which is expected to result in a 
pro-fibrotic effect by preventing the Smad7-induced negative regulation of TGF-β/SMAD 
signaling. Additionally, a significant suppression of Hnf4a, the master regulator of 
hepatic differentiation, was also observed in the PCK rat livers.  
Mast cells (MCs) are immune cells involved in many liver diseases and release 
mediators such as histamine from preformed granules found in their cytoplasm. In fact, 
previously published data demonstrate that histamine induces proliferation of 
cholangiocytes, which are the precursors of the cyst wall epithelial cells (CWEC) in 
CHF. We observed MC infiltration in the hepatic periportal areas, but not in the kidneys, 
in polycystic kidney (PCK) rats. Therefore, we hypothesized that MCs contribute to 
hepatic cyst growth in PCK rats. To test this hypothesis, we treated PCK rats with one 
of two different mast cell stabilizers, cromolyn sodium (CS) or ketotifen, or saline from 
PND 15 to PND 30. We confirmed that CS and ketotifen treatment decreased MC 
degranulation in liver. Interestingly, we observed an increase in liver/body weight ratio 
after CS and ketotifen treatment paralleled by a significant increase in cyst size. In 
contrast, we saw a decreased kidney/body weight ratio paralleled by a significant 
decrease in individual cyst size after CS treatment. We excluded the direct effect of CS 
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on cyst growth by treating isolated cyst wall epithelial cells (CWECs) and a mouse 
model (no MC observed) of ARPKD with CS. Taken together, these data demonstrate 
that hepatic and renal cysts are differentially regulated by MC granule contents in PCK 
rats.  
RNA-seq analysis suggested that TEA Domain Transcription Factor 4 (Tead4), a 
transcription factor in Hippo signaling pathway, is upregulated in PCK rats. Hippo 
signaling pathway is a conserved signaling that plays critical roles in liver size control 
and cell proliferation. Our preliminary data suggested that YAP, the downstream effector 
of the Hippo signaling pathway, was increased in proliferating CWECs in PCK rats and 
in human ARPKD patients. Consistently, there was increased expression of YAP target 
genes, Ccnd1 (cyclin D1) and Ctgf (connective tissue growth factor), in PCK rat livers. 
Extensive expression of YAP and its target genes was also detected in human 
CHF/ARPKD liver samples. Therefore, we hypothesized that YAP plays a role in CWEC 
proliferation in CHF/ARPKD. We inhibited YAP activity pharmacologically using 
verteporfin and genetically using short hairpin (sh) RNA in primary liver CWECs. We 
found that CWEC proliferation was significantly reduced. These data indicate 
that increased YAP activity, possibly through dysregulation of the Hippo signaling 
pathway, is associated with hepatic cyst growth in CHF/ARPKD. 
In RNA-seq analysis, we found that Cd44 was upregulated in PCK rats from PND 
15 to PND 90. Hyaluronan (HA), a CD44 ligand, is a ubiquitous, anionic 
glycosaminoglycan present in the extracellular matrix (ECM). HA is implicated in liver 
injury, inflammation, and fibrogenesis. Our study showed an increased HA level in livers 
from PCK rats and polycystic liver disease patients relative to healthy controls. HA 
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accumulation could be due to an increased Has1 (a HA synthase) expression and 
decreased expression of HA degrading enzymes. Therefore, we hypothesized that HA 
plays a pathogenic role in progression of CHF/ARPKD. Future studies can be 
performed to test the role of HA in CHF/ARPKD by genetically deleting Has enzymes or 
the HA receptor, CD44, in PCK rats or in Pkhd1 mutant mice 
Taken together, CHF/ARPKD is a hepatobiliary disease that is regulated by a 
‘pathogenic triumvirate’ (cell proliferation/cyst growth, inflammation, fibrosis). My studies 
aimed to discover novel mechanisms driving CHF/ARPKD and investigated how MC, 
and YAP, regulated the ‘pathogenic triumvirate’ in CHF/ARPKD. Moreover, we identified 
and upregulation of HA and Cd44 in PCK rats the significance of which can be explored 
in future studies. Overall, these studies have uncovered several new avenues for 
additional research into the mechanisms of cell proliferation/cyst growth, inflammation, 
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1.1 AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE 
(ADPKD) AND AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY 
DISEASE (ARPKD) 
Polycystic kidney disease is a genetic disorder that is inherited as either 
autosomal dominant (ADPKD) or autosomal recessive (ARPKD). In Table 1.1.1, we 
summarize the features of ADPKD and ARPKD from different aspects. ADPKD is more 
common compared to ARPKD with an occurrence of 1:400 – 1:1000 (Torres et al. 
2007). It is caused by mutations in gene PKD1 (~78% pedigrees), PKD2 (~15% 
pedigrees), or no mutation detected (~9% pedigrees) (Harris et al. 2014). ADPKD is 
characterized by progressive development of cysts during the lifetime of the patient, 
resulting in bilateral renal enlargement and often end-stage renal disease (ESRD) 
(Torres et al. 2007). Extrarenal manifestations include intracranial aneurysms, 
polycystic liver disease, and vascular abnormalities (Pirson et al. 2002, Torres 2007, 
Nowak et al. 2017).  
Autosomal recessive polycystic kidney disease (ARPKD) is a rare genetic 
disorder that occurs in 1:20,000 live births. It develops in utero and is mainly diagnosed 
in pregnancy or in the immediate neonatal period. Among affected patients, 
approximately 30% die shortly after birth, primarily of pulmonary insufficiency (Zerres et 
al. 1998). Patients who survive the neonatal period present with a broad spectrum of 
symptoms involving the kidneys, liver, and pancreas. Renal manifestations are 
characterized by the presence of cysts that are derived from dilated collecting ducts and 
distal tubules (Osathanondh et al. 1964, Blyth et al. 1971). A significant portion of 
patients will progress to end stage renal disease either during the first decade or during 
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adolescence (Bergmann et al. 2005). A minority of patients develop pancreatic 
abnormalities consisting of cysts and fibrosis (Bernstein et al. 1987, Williams et al. 
2008). All patients with ARPKD develop some degree of congenital hepatic fibrosis 
(CHF), which, as the name would suggest, is present at birth. CHF is characterized by 
bile duct dilation resulting in eventual development of cysts and pericystic fibrosis in the 
liver (Shneider et al. 2005, Turkbey et al. 2009). Accompanying cyst growth and fibrosis, 
recent reports suggest that inflammation is also present, and likely contributes to 
disease pathogenesis and/or progression (Tracy et al. 1996, Flores et al. 2008, 
Nakanuma et al. 2010, Locatelli et al. 2016). Aside from management of symptoms, and 
liver and/or kidney transplant, no effective pharmacologic therapies exist for 




Table 1.1.1. Comparison between ADPKD and ARPKD.  
Type Occurrence Mutated gene Symptoms 






Polycystic liver disease 
Vascular abnormalities 
ARPKD 1:20,000 (Neonates) PKHD1 (fibrocystin) 
Cystic kidney, liver 
Pulmonary hypoplasia 
Portal hypertension 




1.2 GENETIC DEFECTS AND CURRENT THERAPIES IN CHF/ARPKD 
CHF/ARPKD is caused by mutations in the PKHD1 gene on chromosome 6p12. 
PKHD1 extends over 470 kb, includes a minimum of 86 exons and encodes a 4,074-
amino-acid protein called fibrocystin/polyductin. Fibrocystin is predicted to be a 
receptor-like protein that consists of a large glycosylated extracellular region, a single 
transmembrane domain, and a short cytoplasmic tail (Onuchic et al. 2002, Ward et al. 
2002). Fibrocystin is expressed in the primary cilia of epithelial cells. 
Immunohistochemistry studies suggest that fibrocystin is located in renal collecting 
ducts and loops of Henle, pancreatic epithelial ducts, and hepatic biliary ducts 
(Menezes et al. 2004). Different mutations in PKHD1 have been described in human 
ARPKD patients, including missense mutations, deletion/insertion mutations, and 
splicing mutations. Among all types of mutations found in PKHD1, about 45% of them 
are predicted to truncate fibrocystin (Bergmann et al. 2003). Disease in patients carrying 
two truncating mutations is usually more severe, whereas patients bearing missense 
mutations exhibit a milder phenotype (Harris et al. 2004).  
There is no pharmacologic cure for CHF/ARPKD. Treatment mainly focuses on 
management of symptoms and includes therapies for cardiac hypertension, chronic 
liver/kidney disease, cholangitis, and portal hypertension (Guay-Woodford et al. 2003). 
Hypertension associated with chronic kidney disease occurs at the early stage of 
disease and is regulated by the renin-angiotensin system (RAS) (Goto et al. 2010). 
Hypertension in ARPKD is treated empirically. Angiotensin converting enzyme (ACE) 
inhibitors and angiotensin II receptor blockers (ARBs) are considered the main 
treatment options in ARPKD patients (Gunay-Aygun et al. 2006, Turkbey et al. 2009). If 
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kidney failure occurs, patients undergo dialysis or kidney transplantation. Treatment for 
CHF/ARPKD is more challenging since patients have recurrent cholangitis and an 
increased risk of malignant cholangiocarcinoma after liver transplantation (Gunay-
Aygun et al. 2006). Other therapeutic strategies include targeting components of the 
cAMP signaling pathway since cAMP levels are increased in cyst wall epithelial cells 
(CWEC) and drive CWEC proliferation. Octreotide and pasireotide, two somatostatin 
analogs, decrease CWEC proliferation in PCK rats in vitro and inhibit hepatorenal cyst 
growth in PCK rats in vivo by reducing cAMP levels. Consistently, clinical trials in 
patients with polycystic liver disease (PLD) and ADPKD showed that octreotide or 
lanreotide are well tolerated, and decrease total liver volume by 4% - 6% (Masyuk et al. 
2015), suggesting that somatostatin analogs could be effective as therapeutic drugs for 
CHF/ARPKD patients.  
 
 
1.3 ANIMAL MODELS OF ARPKD 
Several rodent models of human ARPKD are available to study the mechanisms 
of disease and to test therapeutic strategies (Table 1.1.2). One of the best-
characterized models is the polycystic kidney (PCK) rat, derived from Sprague-Dawley 
(SD) rats at Charles River, Inc. (Katsuyama et al. 2000). The PCK rat carries a 
spontaneous splicing mutation, IVS35–2A→T, in the rat Pkhd1 gene (Ward et al. 2002). 
PCK rats bear hepatic and renal cysts, and associated fibrosis, similar to human 
ARPKD (Lager et al. 2001). The lifespan of a PCK rat is about 1.5 years, and they 
develop numerous cysts in kidneys and liver by one year of age (Nagao et al. 2012).  
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In mice, the congenital polycystic kidney (cpk) mouse mimics human ARPKD. 
This mouse harbors a spontaneous mutation in cpk gene, the gene that encodes a 145-
amino acid protein termed cystin. Cystin is mainly located in the axoneme of the primary 
cilia found in the kidney proximal tubules and collecting ducts and in the cholangiocytes 
found in the liver (Avner et al. 1987, Hou et al. 2002). Cpk mice, on the BALB/c 
background, exhibit both renal and extrarenal manifestations associated with cystin 
mutations (Ricker et al. 2000). When on a C57Bl/6J background, cpk mice do not have 
extrarenal pathology (Preminger et al. 1982), limiting the utility of this model for those 
interested in studying CHF/ARPKD. In addition, a Pkhd1del2/del2 mouse model, which 
lacks exon 2 of the mouse Pkhd1 gene, also reproduces the human ARPKD liver 
pathology. Both genders develop hepatic cysts and fibrosis by 3 months as a result of 
biliary ductal plate malformation (Woollard et al. 2007). Another widely accepted murine 
model with Pkhd1 mutation was generated by Christopher Ward and colleagues. In this 
model, the Pkhd1 gene was transcriptionally silenced by inserting a loxP flanked STOP 
(LSL) cassette into intron–2. The Pkhd1LSL(−)/LSL(−) mice, both male and female, develop 
liver cysts and fibrosis at 3 months of age (Bakeberg et al. 2011). Among all rodent 
models for ARPKD, the PCK rat is one of the most well-accepted models because the 







Table 1.1.2. Current rodent models of ARPKD.   
Model Species Liver phenotype 
Kidney 
phenotype Others Reference 














disease Cysts None 
(Gattone et 
al. 1988) 






et al. 2007) 




et al. 2011) 












et al. 2008) 







et al. 2008) 
 
 
1.4 MECHANISMS OF CYSTOGENESIS IN ARPKD 
Although the mechanisms of cystogenesis are not well characterized in human 
ARPKD, a study using PCK rats suggested a possible link between cystogenesis and 
ciliary dysfunction (Masyuk et al. 2004). Primary cilia, microtubule-based organelles, 
extend from the surface of eukaryotic cells. Primary cilia are non-motile cilia containing 
a “9+0” axoneme, and function as mechano-, osmo-, and chemosensors that deliver 
signals from the extracellular environment into the cell (Masyuk et al. 2008). The 
abnormal primary cilia in PCK rat cholangiocytes may compromise their sensory 
organelle function in response to fluid secretion or fluid flow. Recent research suggests 
that primary cilia are also important components of multiple signaling pathways such as 
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the hedgehog and PDGF-A signaling pathways, and mutation of PKHD1 gene may 
disrupt these pathways contributing to cyst formation (Huangfu et al. 2003, Schneider et 
al. 2005).  
Hepatic cystogenesis in human ARPKD patients is characterized by abnormal 
remodeling of the ductal plate from the double cell layer during embryonic liver 
development. Clinical manifestations include dilated bile ducts, an increased number of 
bile ducts, and abnormal branching (Turkbey et al. 2009). It remains to be determined if 
hepatic cysts in ARPKD become disconnected from the biliary tree as is the case for 
ADPKD. (Patterson et al. 1982). Cyst development in PCK rat liver has been well-
described by Dr. Nicholas LaRusso’s group (Perugorria et al. 2014, Wills et al. 2014, 
Masyuk et al. 2015). They found that (1) hepatic cysts are derived from bile duct 
segments due to ductal plate malformation during development and (2) most cysts 
become isolated from biliary tree by 6 months of age (Masyuk et al. 2004).  
Along with cyst formation, the mechanisms of cyst expansion are proposed to be 
the result of: (1) cholangiocyte hyperproliferation, (2) cell-matrix interactions, and (3) 
fluid secretion (Figure 1.4.1, (Gradilone et al. 2010)). Many factors can regulate these 
processes through different signaling pathways and are briefly described below: (1) 
Intracellular cyclic adenosine monophosphate (cAMP) is likely the major driver of 
hepatic cyst growth (Masyuk et al. 2015). In addition, cAMP levels are elevated in PCK 
rat cholangiocytes as compared to cholangiocytes from control rats. Octreotide, a 
somatostatin analog, reduces hepatic and renal cyst expansion in PCK rats by 
decreasing cAMP levels (Masyuk et al. 2007). Another factor that contributes to CWEC 
proliferation is low intracellular [Ca2+], and is observed in CWECs from PCK rat livers 
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(Banales Jú et al. 2009). Activation of Trpv4, a calcium-permeable cation channel 
expressed in normal cholangiocytes, increases intracellular calcium levels and 
suppresses proliferation of cholangiocytes isolated from PCK rats in vitro (Gradilone et 
al. 2010). (2) Remodeling of extracellular matrix includes alteration of extracellular 
matrix composition, basement membrane thickness, and the activities of matrix 
metalloproteases (MMP) and their inhibitors, all of which can lead to cyst expansion 
(Wilson 2004). (3) In ARPKD, little is known about how fluid secretion impacts hepatic 
cyst expansion (Figure 1.4.1). Previous data suggest that cystic epithelia can respond to 
secretin and secrete fluid through activating a cAMP-dependent signaling pathway 
(Everson et al. 1990, Qian 2010).  
In addition, there are other factors that regulate CWEC proliferation. Recent 
studies have shown that deregulation of the Hippo signaling pathway results in 
increased expression and activity of its downstream effector Yes-associated protein 
(YAP), which is involved in a number of fibro-proliferative hepatic disorders including 
hepatic fibrosis, hepatocellular carcinoma and cholangiocarcinoma (Camargo et al. 
2007, Pan 2010, Li et al. 2012, Septer et al. 2012). When the Hippo signaling pathway 
is ‘on’, activation of LATS1/2 kinases directly phosphorylate YAP, which inhibits YAP 
nuclear translocation. When the Hippo signaling pathway is ‘off ’, YAP is translocated to 
the nucleus and binds to different transcription factors to regulate target genes involved 
in cell proliferation, cell survival, and apoptosis (Di Cara et al. 2015, Yu et al. 2015). A 
previous study showed increased YAP activation in kidney cyst epithelial cells from 
ADPKD and ARPKD patients (Happe et al. 2011); however, the role of YAP in hepatic 
cyst development in CHF/ARPKD is not known. It is known that primary cilia in cystic 
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cholangiocytes are malformed and dysfunctional, it is plausible to propose that YAP is 
activated as the result failing to function properly as a sensory organ.  
Renal cysts in ARPKD are commonly described as dilated collecting ducts (Kern 
et al. 2000). Compared to what is observed in ADPKD, dilated collecting ducts and 
distal tubules lined with cuboidal or columnar epithelial cells which remain connected to 
the urinary system (Bergmann 2015). It remains unclear in ARPKD whether or not cysts 
with squamous epithelial cells detach from the tubular segment from which they are 
derived (Calvet et al. 2001). Cyst formation and expansion are associated with 
increased proliferation of renal epithelial cells (Nadasdy et al. 1995) and altered fluid 
secretion (Veizis et al. 2004). Recent data suggest that cAMP induces renal epithelial 
cell proliferation and promotes cyst growth by activating PKA/B-Raf/MAPK pathways in 
CWECs from ARPKD patients (Yamaguchi et al. 2006). Similarly, renal epithelial cells 
also exhibit a lower level of intracellular [Ca2+], and sustained reduction of intracellular 
[Ca2+] in normal cells induces a cAMP-growth stimulated phenotype (Yamaguchi et al. 
2006). In addition, an increased level of epidermal growth factor (EGF) is demonstrated 
in renal cyst fluid, which is consistent with an overexpression of EGF receptor (EGFR) 
mRNA and protein in renal epithelia in cpk mice (Horikoshi et al. 1991). However, the 
administration of EGFR tyrosine kinase inhibitor does not protect PCK rats from 
developing renal cysts and liver cysts, possibly due to an increased level of cAMP after 
treatment (Torres et al. 2004). In addition, arginine vasopressin (AVP) V2 receptor 
antagonists have shown beneficial effects on slowing renal disease progression in PCK 
rats (Torres 2008). Administration of the AVP receptor antagonist OPC-31260 to PCK 
rats reduced the renal accumulation of cAMP and renal cyst progression by the 
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inhibition of Ras/B-Raf/ERK pathway (Gattone et al. 2003, Wang et al. 2005). 
Tolvaptan, a V2R antagonist, slowed the increase in total kidney volume and the decline 
in kidney function in patients with ADPKD over a 3-year preclinical study (Torres et al. 
2012). In 2018, Tolvaptan was approved by the Food and Drug Administration for the 
treatment of ADPKD (Ostrowski et al. 1993). Considering the fact that V2R is not 
expressed in liver, CHF/ARPKD patients may not benefit from Tolvaptan. This 
emphasizes the persistence of a critical need for a pharmacological agent specific, and 
























Fig.1.4.1. Schematic representation of cystogenesis in ARPKD. Cystogenesis is 
initiated with mutations in gene PKHD1, encoding for fibrocystin. Biliary/renal epithelial 
cells with mutations proliferate and become an isolated cyst. Cyst growth can be 
promoted by cell proliferation, cell-matrix interactions, and fluid secretion. cAMP 
promotes cyst growth cyst growth. Other factors such as Yes-associated protein (YAP), 
















1.5 MECHANISMS OF FIBROSIS IN ARPKD 
Liver fibrosis typically results from chronic liver injury in conjunction with the 
accumulation of extracellular matrix (ECM) proteins synthesized by myofibroblasts 
(MFB). In the liver, the major cell types that contribute to MFB formation are hepatic 
stellate cells (HSC) and portal fibroblasts (PF). Residing in the space of Disse, HSCs 
are the principle cell type responsible for collagen synthesis in response to liver injury or 
changes in ECM stiffness (Gabele et al. 2003). HSCs are also activated by various 
mediators released from Kupffer cells, the liver-resident macrophage population, and 
include transforming growth factor-beta (TGF-β) and tumor necrosis factor-alpha (TNF-
α) (Matsuoka et al. 1990). In addition, connective tissue growth factor (CTGF) is 
produced by multiple cells types in liver, and it promotes the activation of HSCs (Huang 
et al. 2012). When HSCs are activated, they convert from quiescent cells to 
proliferative, fibrogenic, and contractile MFB, and release a variety of inflammatory 
chemoattractants such as monocyte chemoattractant protein-1 (MCP-1) to recruit 
monocytes to the liver (Marra et al. 1998). PFs are found in the portal tract area, and 
play a predominant role in biliary fibrosis (Dranoff et al. 2010). Although both cell types 
express alpha smooth muscle actin (αSMA) upon activation, research suggests that the 
MFB population that contributes to CHF/ARPKD is likely derived from PFs (Wen 2011). 
Similar to HSCs, TGF-b and CTGF are involved in the activation of PFs (Sedlaczek et 
al. 2001, Li et al. 2007, Borkham-Kamphorst et al. 2014). By contrast, TNF-α does not 
seem important for PF activation or fibrogenic potential (Dranoff et al. 2010). In addition 
to their role in biliary fibrosis, activated portal MFB regulate cholangiocyte proliferation 
through activating P2Y receptors on bile duct epithelium (Jhandier et al. 2005). 
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Following the activation of HSCs or PFs to MFB, two major events occur which promote 
fibrogenesis. First, activated MFB directly increase the synthesis and deposition of ECM 
proteins. Second, the MFB proliferate and amplify the fibrotic response (Parsons et al. 
2007).  
Matrix degradation is an important mechanism to reverse fibrosis or cirrhosis and 
can restore normal liver architecture. Two kinds of matrix degradation mechanisms 
exist: “pathologic matrix degradation” that disrupts low density matrix and “restorative 
matrix degradation” that degrades excess scar (Friedman 2003). Matrix remodeling is 
carried out through a fine balance between activities of MMPs and their inhibitors. 
MMPs are a family of enzymes secreted as proenzymes and are activated by proteolytic 
cleavage. They play a pivotal role in the regression of liver fibrosis by degrading ECM 
and inducing MFB apoptosis. Expression of tissue inhibitors of metalloproteinase 1 
(TIMP-1) promotes fibrosis, first, by inhibiting MMP activity, and second, by inhibiting 
MFB apoptosis (Murphy et al. 2002). Figure 1.5.1. summarizes the mechanisms of liver 
fibrosis in CHF/ARPKD.  
The connection between cyst growth and fibrosis in CHF/ARPKD is thus far 
unclear. Unlike some of the liver diseases, liver injury due to ARPKD may not be the 
initial event that causes HSC activation and fibrosis. Instead, cystogenesis may disrupt 
normal ECM remodeling and induces fibrogenesis. This hypothesis is supported by the 
fact that HSCs and PFs are activated and differentiate into MFB when 
microenvironmental stiffness increases (Li et al. 2007, Olsen et al. 2011); enlarging 
cysts may promote this increase in mechanical stiffness and facilitate PF and HSC 
activation. Recent evidence suggests that bile duct epithelia directly regulate PF 
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proliferation and PF transdifferentiation to MFB via release of MCP-1 (Kruglov et al. 
2006). These data indicate that release of MCP-1 released by cystic epithelia is likely an 
additional link between cyst growth and fibrosis by recruiting macrophages, and 
inhibition of which could have therapeutic effects in CHF/ARPKD. 
A polysaccharide called hyaluronan (HA) regulates both cholangiocyte 
proliferation and liver fibrosis (Guechot et al. 1995, He et al. 2008). HA is composed of 
repeating disaccharides of D-glucuronic acid and N-acetylglycosamine, and It can be 
found in association with the collagen of our skin, joint synovial, and eye vitreous fluid. 
Increased serum HA level has been detected in patients with liver diseases, such as 
non-alcoholic fatty liver disease (Suzuki et al. 2005), alcoholic liver diseases (Stickel et 
al. 2003, Gudowska et al. 2016), hepatitis C (Guechot et al. 1995, Gudowska et al. 
2016), primary biliary cirrhosis (Nyberg et al. 1988), and hepatocellular carcinoma (Li et 
al. 2016). HA has been used as a biomarker for liver disease severity (Gudowska et al. 
2016). The production of HA increases as a critical component of collagen deposition 
under various inflammatory conditions (Engstrom-Laurent et al. 1985, Levesque et al. 
1988, Bachem et al. 1989, Savani et al. 2000). In addition, a decreased number of HA 
uptake receptor CD44 on injured sinusoidal endothelial cells might also cause an 
increased level of HA in serum (Tamaki et al. 1996). Recently, a study using bile duct 
ligated-rats to mimic cholestasis suggests that biliary epithelial cells are the source of 
CD44, and HA-CD44 interaction promotes biliary epithelium proliferation (He et al. 
2008). However, the role of HA in CHF/ARPKD is unknown.  
Compared to what has been established regarding development of hepatic 
fibrosis, little is known about renal fibrosis in regarding the mechanisms and 
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consequences in ARPKD. Although patients exhibit very different renal symptoms, they 
always develop some degree of interstitial fibrosis around renal cysts (Avni et al. 2002). 
In PCK rats, renal interstitial fibrosis is not evident until 70 days of age, and renal 
disease is more severe in males than in females (Lager et al. 2001). Interestingly, 
administration of a B-type natriuretic peptide, a guanylyl cyclase A agonist, in PCK rats 
can effectively reduce renal cyst size and fibrosis through regulating Ca2+ level. This 
suggests that guanylyl cyclase A-cGMP axis may provide a new insight to ARPKD 
therapy (Holditch et al. 2017). Glycogen synthase kinase-3β (GSK3β), a 
serine/threonine protein kinase, is increased in renal cyst-lining epithelia from a mouse 
model of ARPKD, and inhibition of its activity reduces renal cyst expansion (Tao et al. 
2015). GSK3β also promotes renal fibrosis by activating TGF-b signaling in a mouse 
model of renal fibrosis induced by ischemia-reperfusion injury (Singh et al. 2015). 
Therefore, GSK3β is a key pathogenic determinant in ARPKD, and pharmacological 










Fig.1.5.1. Schematic representation of fibrogenesis in CHF/ARPKD. Although not 
yet explored in CHR/ARPKD, hepatic cyst expansion may increase liver stiffness and 
induce the activation of myofibroblasts from hepatic stellate cells, portal fibroblasts, and 
perhaps other cell types. Activated myofibroblasts will synthesize collagen, decrease 
expression of matrix metalloproteases (MMPs), and increase expression of their 
inhibitor metalloproteinase 1 (TIMP-1). All of these contribute to liver fibrosis 
development and may in turn affect hepatic cyst growth.  
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1.6 MECHANISMS OF INFLAMMATION IN ARPKD 
In addition to cyst growth and fibrosis, inflammation is another pathological 
feature of CHF/ARPKD. Although inflammation in the liver has not been well studied as 
that in the kidney, immune cells such as mast cells (MC) accumulate in the pericystic 
areas in livers of human CHF/ARPKD patients (Ozaki et al. 2005). Consistently, we 
have observed pericystic MC infiltration in PCK rats (see chapter III). Tryptase, a MC 
granule component, was increased in serum from PCK rats compared to its level in SD 
rats. Histamine level didn’t differ between PCK rats and SD rats. Inhibition of MC 
degranulation and histamine release with cromolyn sodium, a MC stabilizer, decreases 
cholangiocyte proliferation in bile duct ligation-induced cholestasis (Kennedy et al. 
2014), suggesting MC may also contribute to cholangiocyte-derived, CWEC 
proliferation. In addition to MCs, other immune cells are also found in patients with PKD. 
For example, CD45+, a molecule found on all leukocytes, and CD4+ lymphocytes were 
identified in the interstitium of rodent models of PKD and ADPKD patients (Kaspareit-
Rittinghausen et al. 1989, Takahashi et al. 1991, Zeier et al. 1992, Vogler et al. 1999). 
The significance of lymphocytes has not been addressed in PKD, which requires 
additional study. Further, an increased amount of complement protein 3 (C3a), a potent 
pro-inflammatory molecule and chemotactic agent, is detected in kidneys from cpk, 
BALB/c-bpk, and FVB-orpk mice, all of which are mouse models of ARPKD (Mrug et al. 
2008). Taken together, these data suggest that activation of innate and adaptive 
immune effector cells and associated proteins contribute to progression of PKD. 
Although PKD is not primarily considered an inflammatory disorder, accumulating 
evidence suggests that inflammation occurs in the early stage of the disease and may 
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also drive disease progression. For example, macrophage infiltration is found in the 
renal interstitium in human ADPKD patients with kidney failure (Zeier et al. 1992). 
Activated macrophages stimulate vascular endothelial cell proliferation in vitro (Polverini 
et al. 1977). Further, TNF-α, an inflammatory cytokine, is present in renal cyst fluid of 
human ADPKD, and induces renal cyst formation through regulating polycystin-2 (Li et 
al. 2008). In ARPKD, M2-like macrophages are present in kidneys from ARPKD patients 
and cpk mice, and depletion of macrophages in cpk mice restrains pathological 
enlargement of kidneys (Swenson-Fields et al. 2013). In PKHD1del4/del4 mice, cystic 
cholangiocytes secrete a range of chemokines, such as chemokine (C-X-C motif) 
ligands 1, 10, and 12, which stimulate M1- and M2- macrophage recruitment to portal 
regions of the liver. Recruited macrophages release pro-inflammatory cytokines such as 
TNFa (M1) and TGFb1 (M2), both of which up-regulates avb6 integrin on cystic 
cholangiocytes. In PKHD1del4/del4 mice, the proportion of M1 macrophages is high 
initially, but the contribution of M2 macrophages increases progressively at 9 months. 
avb6 is an activator of latent local TGFb1, and activation of which promotes liver fibrosis 
(Figure 1.6.1, (Locatelli et al. 2016)). Depletion of macrophages by clodronate in 
PKHD1del4/del4 mice treated from 3 to 6 months could reduce macrophage infiltration, 
myofibroblast activation, and halt liver fibrosis progression (Locatelli et al. 2016). This 
supports a role of macrophages in the progression of ARPKD. Work from others has 
found increased MCP-1 in kidneys from PCK rats (Zoja et al. 2015). Consistent with a 
role for MCP-1 and macrophage infiltration in progression in PKD, inhibition of MCP-1 
synthesis with bindarit reduces renal inflammation and renal dysfunction, but did not 
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attenuate cyst growth (Zoja et al. 2015). Whether or not MCP-1 depletion affected 










































































Fig.1.6.1. Schematic representation of inflammation in CHF/ARPKD. Biliary 
epithelia with PKHD1 mutation secrete chemokines such as CXCL1. CXCL10, and 
CXCL12, which recruit M1- and M2- macrophages to the portal area. M1- and M2- 
macrophages produce TNFa and TGFb that further cause avb6-induced activation of 
TGFb. TGFb activation eventually promotes liver fibrosis progression (Locatelli et al. 
2016). Mast cells release histamine, tryptase, and chymase. They directly and indirectly 
act as chemoattractants for inflammatory cells (Zoja et al. 2015).  
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1.7 THE ‘PATHOGENIC TRIUMVIRATE’ IN CHF/ARPKD: INSIGHTS 
INTO THE DEVELOPMENT OF NEW THERAPIES 
Although mutations in the human PKHD1 gene, or mutations in PKHD1 orthologs 
in rats and mice, are required for development of CHF/ARPKD, other factors are also 
involved in disease progression. It is from a review of the published literature and 
summarized in this chapter that we propose a ‘pathogenic triumvirate’ in CHF/ARPKD 
which includes three factors, cyst growth, fibrosis, and inflammation, as mediators 
contributing to disease progression (Figure 1.7.1). Despite recent advances in our 
understanding of what contributes to the initial pathology of CHF/ARPKD, less is known 
about the molecular mechanisms regulating continued cyst growth, progression of 
fibrosis, and how inflammation contributes to these interrelated processes. Furthermore, 
whether or not a common mechanism drives all members of the ‘pathogenic triumvirate’ 
is also not known. We propose that leveraging what we do know about the CHF/ARPKD 
pathogenesis in the context of the pathogenic triumvirate will lead the way to new 
research and possibly, new therapies for this disease. For example, finding a central 
mechanism that regulates all three components would be an attractive target for the 
development of new pharmacologic approaches to manage CHF/ARPKD. Alternatively, 
if a common mechanism does not exist, therapeutically targeting each member of the 









Figure 1.7.1: A ‘pathogenic triumvirate’ in congenital hepatic fibrosis (CHF) in 
autosomal recessive polycystic kidney disease (ARPKD).  
Published data suggest that cyst growth, fibrosis, and inflammation drive CHF/ARPKD 
(solid purple arrows). We propose that relationships exist between cyst growth, fibrosis, 
and inflammation which drive progression of CHF/ARPKD (black, double-headed 
arrows with broken lines). Targeting a single pathway which drives each of the 
triumvirate members, or targeting multiple members concurrently, may provide better 







1.8 STATEMENT OF PURPOSE 
ARPKD is a severe monogenic disorder that can affect both liver and kidney. 
Among all affected patients, approximately 30% die shortly after birth due to pulmonary 
insufficiency (Zerres et al. 1998). There is no cure besides liver/kidney transplantation. 
CHF is present as bile duct dilation resulting in eventual development of cysts and 
pericystic fibrosis in the liver (Shneider et al. 2005, Turkbey et al. 2009). The 
mechanisms behind hepatic cystogenesis and fibrogenesis are still unknown. Due to 
these reasons, my dissertation research aims to understand the mechanisms of cyst 
and fibrosis development in ARPKD, and to identify new targets for therapeutic 
purposes. To achieve this objective, we used mouse and rat models of CHF/ARPKD to 
study the mechanisms of disease development, identify potential therapeutic targets, 
and test novel interventional strategies to attenuate or halt disease progression, if not 
reverse disease pathogenesis entirely.  
RNA-seq is a high-throughput sequencing assay that can be used for discovering 
differentially expressed genes (Mortazavi et al. 2008, Trapnell et al. 2010). Recent 
studies suggest that RNA-seq is more accurate than microarray in a large dynamic 
range of gene expression (Marioni et al. 2008). RNA-Seq is also more sensitive in 
detecting genes with very low expression and more accurate in detecting expression of 
extremely abundant genes (Zhao et al. 2014). To uncover changes of gene expression 
in CHF/ARPKD at the transcriptional level, we performed RNA-seq in SD as control and 
PCK rats at different time points. Our sequencing data provided us a better 
understanding of the disease and potential targets for future study.  
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Our RNA-seq analysis suggested that the Hippo signaling pathway was activated 
in PCK rats. Previous studies show that YAP and TAZ (a related transcriptional 
coactivator) are key activators of fibroblasts, and they sustain fibrosis by activating 
fibroblasts (Liu et al. 2015). As an oncoprotein, YAP activation is found in several 
human cancers (Zhao et al. 2007), and it plays a key role in the Hippo signaling 
pathway to control cell proliferation in response to cell contact (Zhao et al. 2007). 
Finally, YAP activation promotes endothelial cell proliferation and inflammatory 
response in atherosclerosis (Wang et al. 2016). Therefore, it is logical to predict that the 
Hippo signaling pathway could be the central pathway regulating each member of the 
pathogenic triumvirate in CHF/ARPKD. Our preliminary data suggest that YAP activity 
was increased in PCK rats and in ARPKD patients (Jiang et al. 2017). We hypothesized 
that YAP drives cyst progression in CHF/ARPKD.  
In addition to cyst growth and fibrosis, inflammation is another pathological 
feature of CHF/ARPKD. In CHF/ARPKD patients, immune cells such as mast cells (MC) 
accumulate in hepatic pericystic areas (Ozaki et al. 2005). MCs are innate immune cells 
with a broad range of effector activity (Urb et al. 2012). They synthesize and store many 
molecules including chymase, tryptase and histamine in large cytoplasmic granules 
which they release during tissue injury and in response to other stimuli (Metcalfe et al. 
1997). Inhibition of MC degranulation and histamine release with cromolyn sodium, a 
MC stabilizer, decreases cholangiocyte proliferation in bile duct ligation-induced 
cholestasis (Kennedy et al. 2014), suggesting MC may also contribute to cholangiocyte-
derived, CWEC proliferation. Therefore, we hypothesized that MC plays a role in 
CHF/ARPKD progression.  
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HA-CD44 interaction is shown to enhance cholangiocyte proliferation and liver 
fibrosis in cholestasis (He et al. 2008). We found that Cd44 expression was upregulated 
in PCK rats by real-time PCR and RNA-seq. Increased HA accumulation was also 
detected in liver samples from PCK rats and human ARPKD patient. Therefore, we 
hypothesized that HA-CD44 interaction may drive pathogenesis of CHF/ARPKD. 
CHF/ARPKD is a hepatobiliary disease with no cure available. We hypothesized 
that there is a ‘pathogenic triumvirate’ that regulates disease progression. The objective 
of this dissertation is to expand our understanding of this disease at the molecular level 
and to identify central molecular mediators of the ‘pathogenic triumvirate’. By testing 
multiple hypotheses in animal models of CHF/ARPKD, we expected to identify novel 



















CHAPTER II: DISCOVERING MOLECULAR MEDIATORS OF 

























Congenital hepatic fibrosis (CHF) is a neonatal hepatic inherited disease 
characterized by the presence of hepatic cysts derived from dilated bile ducts and a 
robust, pericystic fibrosis. To characterize early disease progression at the molecular 
level, we performed an RNA-seq analysis on liver samples from PCK rats, a model of 
CHF, over a time course of postnatal day (PND) 15 to 90. Sprague-Dawley (SD) rats 
were used as controls. The number of differentially expressed genes increased in PCK 
rats over time. Upstream regulator analysis using the Ingenuity Pathway Analysis (IPA) 
predicted activation of several pro-proliferative and pro-inflammatory regulators in PCK 
rats including Ctnnb (catenin beta 1), Mtpn (myotrophin), Rb1 (RB transcriptional 
corepressor 1) and several Stat (Signal transducer and activator of transcription) family 
members (z score ≥ 2). Further, PCK rat livers contained gene signatures consistent 
with decreased activation of Smad7, which inhibits fibrosis. Finally, PCK rat livers 
exhibited significant suppression of Hnf4a, the master regulator of hepatic 
differentiation. Overall, our RNA-seq data suggest that cystogenesis and fibrosis in PCK 
rats is driven by an imbalance between anti and pro-proliferative and anti and pro-







Autosomal recessive polycystic kidney disease (ARPKD) is a hereditary disorder 
caused by mutations in PKHD1 (Onuchic et al. 2002). The clinical spectrum is widely 
variable with multiple organs affected, primarily kidneys and liver. Kidney disease is 
characterized by tubule dilation and focal cyst development from collecting ducts (Blyth 
et al. 1971, Ward et al. 2003). Liver disease in ARPKD is called congenital hepatic 
fibrosis (CHF), which involves development of segmental dilations of bile ducts 
accompanied by periportal fibrosis (Desmet 1992). CHF causes a significant proportion 
of morbidity and mortality in ARPKD patients who develop portal hypertension 
(Shneider et al. 2005). Although the mechanisms of hepatic cyst expansion are not well 
characterized in human ARPKD, different factors, such as cholangiocyte 
hyperproliferation and fluid secretion, have been proposed that contribute to the 
progression of cysts (Gradilone et al. 2010). To study ARPKD, one of the best-
characterized animal models for human ARPKD is the PCK rat, derived from a colony of 
Sprague-Dawley (SD) rats at Charles River, Inc (Katsuyama et al. 2000). As a 
spontaneously occurring inherited model of ARPKD, they bear a striking resemblance 
with human ARPKD pathobiology including hepatorenal cysts and fibrosis (Lager et al. 
2001).  
The mechanisms underlying gene expression involved in CHF/ARPKD 
pathogenesis are not known. We applied RNA-seq technology to analyze liver samples 
from SD rats and PCK rats at different time points after birth. Our data provide a 
significant amount of new information on gene expression changes, upstream 
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regulators changes, and their associated pathways at the transcriptional level in 
CHF/ARPKD.  
We previously proposed a ‘pathogenic triumvirate’ to describe the three pathogenic 
components in CHF/ARPKD, which includes cyst growth, inflammation, and fibrosis 
(Jiang et al. 2016). Using RNA-seq analysis, we found that differentially expressed 
genes, transcription factors, and canonical pathways in PCK can be categorized into 
one of the three components. In addition, we identified several genes and transcription 
factors related to liver development and metabolism in PCK rats that may contribute to 
the pathogenesis of CHF/ARPKD. Overall, our study provides a comprehensive 
characterization of gene expression profile in CHF/ARPKD. By identifying potential 
regulators of the ‘pathogenic triumvirate’ and other possible contributors of 
CHF/ARPKD, we propose several molecular targets of the disease that can be 
informative for therapy in future studies. 
 
2.3 MATERIALS AND METHODS 
 
Animals 
Male and female polycystic kidney (PCK) rats and Sprague-Dawley (SD) rats 
(control strain for PCK) were purchased from Charles River and housed in an AAALAC-
approved vivarium at the University of Kansas Medical Center (KUMC). All animal 
studies were approved by the KUMC Institutional Animal Care and Use Committee 
(IACUC) and were performed in accordance with IACUC guidelines. 
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Sample preparation and RNA isolation 
Liver samples were collected from SD and PCK rats at postnatal day (PND) 15, 
20, 30, and 90 (n = 3 each time point each genotype). Both male and female rats were 
included. Liver pieces (20 – 30 mg) for RNA isolation were transferred to 1.5 mL of 
RNAlater-ICE (Ambion Inc., Austin, TX, USA) and stored at −80 °C overnight before 
use. Total RNA was isolated with an RNeasy Mini Kit (Qiagen, Valencia, CA, USA) after 
homogenization using a MP Biomedicals Fast Prep 24 bead homogenizer with lysing 
matrix D homogenization tubes (Solon, OH, USA). The total RNA concentration and 
purity were determined by a NanoDrop apparatus.  
 
RNA library preparation and data collection 
Total RNA (500 ng) was used to construct the Stranded mRNA-Seq library. 
Briefly, the total RNA fraction was fragmented, reverse transcribed into cDNA, and 
ligated with the appropriate indexed adaptors using the TruSeq Stranded mRNA LT 
Sample Preparation Kit (Illumina, San Diego, CA, USA). The quality of library was 
validated by an Agilent Bioanalyzer. Library quantification was measured using the 
Roche Lightcycler96 with FastStart Essential DNA Green Master. Library concentrations 
were adjusted to 4 nM and pooled for multiplexed sequencing. Libraries were denatured 
and diluted to the appropriate pM concentration followed by clonal clustering onto the 
sequencing flow cell using the TruSeq Paired-End (PE) Cluster Kit v3-cBot-HS. The 
clonal clustering procedure is automated using the Illumina cBOT Cluster Station. The 
clustered flow cell was sequenced on the Illumina HiSeq 2500 Sequencing System 
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using the TruSeq SBS Kit v3-HS. Sequence data is converted to Fastq format from Bcl 
files and de-multiplexed into individual sequences for further downstream analysis. 
 
Bioinformatic analysis for RNA-Seq 
100 bp reads were mapped to the Rnor_5.0 genome using STAR (Dobin et al. 
2013). Transcript assembly was performed with Cufflinks and Cuffmerge (Trapnell et al. 
2012). A counts table was generated using HTSeq-count (Anders et al. 2015) and 
imported into EdgeR (Robinson et al. 2010, McCarthy et al. 2012) to evaluate 
differential gene expression. Volcano plots are created with EdgeR to visualize 
differentially expressed gene pattern. The heatmap and hierarchical clustering were 
analyzed using GenePattern platform at BROAD Institute 
(http://software.broadinstitute.org/cancer/software/genepattern/). Pathway analysis was 
performed using Ingenuity Pathway Analysis (IPA, Ingenuity Systems, 
www.ingenuity.com). Differential expression was determined by absolute fold change > 
1.5 and a q-value (the p-value adjusted for multiple hypothesis correction using the 
Benjamini-Hochberg procedure) less than or equal to 0.05. The IPA upstream analysis 
was performed to predict the activated and inhibited upstream regulators using 
activation of z-score algorithm. The activation Z-score is applied to quantify the 
significance of the concordance between the direction of change of genes (up-/down-
regulated) in a gene dataset and the established direction of change (derived from 
literature) of genes associated with a transcriptional regulator. A z-score ≥ 2 or ≤ -2 is 
considered significantly activated or inhibited. P value of overlap reflects that the 
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overlap between the experimental dataset and a given transcriptional regulator is due to 
a random chance. An overlap p-value≤0.05 was considered significant.  
 
2.4 RESULTS 
Identification of differentially expressed genes in PCK rats over progression of 
CHF/ARPKD.  
The PCK rat liver showed a total of 3163 genes upregulated and 2285 genes 
down regulated over the four time points (Figure 2.4.1A). With increase in time after 
birth, the number of the differentially expressed genes also increased. Figure 2.4.1B 
shows volcano plots of differentially expressed genes in PCK rats from PND 15 to PND 
90. We selected top 100 upregulated genes and top 100 downregulated genes at in 
PCK rats at PND 15, 20, 30, and 90. We found 24 genes were in common. A heatmap 
representation of the transcript levels coupled to a hierarchical clustering of the time 
point was obtained to show the gene pattern in PCK rats (Figure 2.4.1C). Among the 
analyzed time points, Adgrg1, Cdh6, Clec2l, Krt7, Reg3b, and Sncg expression peaked 
at PND 30. Ctgf, Cyp2b2, and RGD1560242 expression decreased from PND 15 to 
PND 90. Ddx39b, Fam111a, Krt20, Lamc2, Lilrb31, Loc10091107, Lyc2, Lypd8, 
Ms4a18, Msln, Nfkbi, and Tead4 expression increased from PND 15 to PND 90 in PCK 
rats (Figure 2.4.1C). At PND 15, the top 10 upregulated and downregulated genes 
ranked according to fold change are described in Table 2.4.1. Similarly, the top 
upregulated and downregulated genes in PCK rats at PND 20, 30, and 90 are 




Figure 2.4.1. Differentially expressed genes in PCK rats at postnatal (PND) 15, 20, 
30, and 90. (A) Number of genes up- or down- regulated in PCK rats at postnatal (PND) 
15, 20, 30, and 90. n = 3 per genotype per time point. Cut off fold change is ± 1.5 
compared to Sprague Dawley (SD) rats at each individual time point, q < 0.05. (B) 
Volcano plots for differentially expressed genes in PCK rats from at PND 15, 20, 30, 
and 90. The horizontal axis is the log2 (fold change) between SD and PCK rats. The -
log10 (FDR) is plotted on the vertical axis. Each gene is represented by one point on 
the graph. (C) Heatmap and hierarchical clustering of four time points (PND 15, 20, 30, 
and 90) by similar expression profiles. The fold change of each gene in PCK rats are 
converted to heatmap color using the mean and maximum values for each gene. The 
intensity scale of the standardized expression values ranges from dark blue (low 
expression) to dark red (high expression). 
 
 35 
Table 2.4.1. Top 10 up- and down-regulated genes In PCK rats at PND 15.  
 
Gene Name Gene Symbol Fold Change q-value 
Up-regulated Genes 
Leukocyte elastase inhibitor A-like LOC100911107 76.62 2.08E-14 
Protease, serine, 32 Prss32 39.19 0.004261265 
TEA domain transcription factor 4 Tead4 38.07 4.70E-12 
Regenerating islet-derived protein 
3-beta Reg3b 32.74 1.67E-08 
LY6/PLAUR domain containing 8 Lypd8 20.06 1.98E-05 
Membrane spanning 4-domains 
A18 Ms4a18 13.18 5.42E-06 
Family with sequence similarity 111 Fam111a 12.31 1.00E-18 
Connective tissue growth factor Ctgf 10.10 2.49E-11 
Cadherin 17 Cdh17 8.93 5.46E-06 
Otogelin-like Otogl 8.85 0.005534415 
Down-regulated Genes 
DExD-box helicase 39B Ddx39b -74.90 3.15E-38 
Hepcidin antimicrobial peptide Hamp -74.79 3.38E-05 
Similar to RIKEN cDNA 
1700028P14 RGD1560242 -54.49 0.001730345 
Urinary protein 3-like AABR07069676.1 -48.67 0.003629237 
NFKB inhibitor like 1 Nfkbil1 -12.71 4.03E-44 
Complement factor H Cfh -11.89 0.000542193 
Epoxide hydrolase 2 Ephx2 -8.24 7.72E-06 
17-beta-hydroxysteroid 
dehydrogenase type 6 LOC100362350 -3.77 5.84E-06 
DNA ligase 4 Lig4 -3.63 2.40E-33 
Regulator of G-protein signaling 16 Rgs16 -3.62 0.02294837 
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Table 2.4.2. Top 10 up- and down-regulated genes In PCK rats at PND 20. 
 
Gene Name Gene Symbol Fold Change q-value 
Up-regulated Genes 
Regenerating family member 3 beta Reg3b 5203.98 3.70E-28 
LY6/PLAUR domain containing 
8(Lypd8) Lypd8 4059.76 3.58E-19 
TEA domain transcription factor 4 Tead4 210.19 4.46E-20 
Leukocyte elastase inhibitor A-like LOC100911107 56.05 1.01E-14 
Membrane spanning 4-domains A18 Ms4a18 34.88 1.96E-10 
Tetraspanin 8 Tspan8 30.07 1.53E-25 
Family with sequence similarity 111 Fam111a 21.52 2.13E-26 
Lipocalin2 Lcn2 17.13 1.23E-08 
Gamma-aminobutyric acid type A 
receptor pi subunit Gabrp 15.06 1.29E-06 
Keratin7 Krt7 14.71 7.25E-16 
Down-regulated Genes 
Similar to RIKEN cDNA RGD1560242 -74.79 3.38E-05 
DExD-box helicase 39B Ddx39b -54.49 0.001730345 
Achaete-scute family bHLH 
transcription factor 1 Ascl1 -11.89 0.000542193 
Adenylate cyclase 1 Adcy1 -8.24 7.72E-06 
Similar to RalA binding protein 1 LOC304239 -3.77 5.84E-06 
NFKB inhibitor like 1 Nfkbil1 -9.48 1.39E-35 
Insulin-like growth factor 2 Igf2 -8.40 1.37E-07 
Angiomotin-like 1 Amotl1 -7.84 1.39E-28 
Adenylate cyclase 10 Adcy10 -6.00 3.07E-06 
Alpha-fetoprotein Afp -5.23 7.25E-10 
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Table 2.4.3. Top 10 up- and down-regulated genes In PCK rats at PND 30. 
 
Gene Name Gene Symbol Fold Change q-value 
Up-regulated Genes 
Regenerating family member 3 beta Reg3b 20353.43 2.48E-37 
Interferon-inducible GTPase 1-like LOC100910934 1837.83 4.52E-06 
LY6/PLAUR domain containing 8 Lypd8 623.59 2.35E-19 
Leukocyte elastase inhibitor A-like LOC100911107 565.93 1.11E-28 
Membrane spanning 4-domains A18 Tead4 253.25 1.51E-23 
Ubiquitin D Ubd 210.70 2.52E-06 
Similar to interferon-inducible GTPase RGD1309362 84.26 6.98E-09 
Gamma-aminobutyric acid type A 
receptor pi subunit Gabrp 55.37 1.03E-11 
Membrane spanning 4-domains A18 Ms4a18 50.83 2.53E-12 
Family with sequence similarity 111, 
member A Fam111a 39.95 2.89E-35 
Down-regulated Genes 
Similar to RIKEN cDNA RGD1560242 -349.90 4.36E-17 
Major urinary protein 4 Mup4 -338.82 3.06E-07 
Urinary protein 1-like1 Rup4 -186.77 2.19E-21 
3 beta- and steroid delta-isomerase 2 Hsd3b2 -64.83 2.72E-09 
Urinary protein 3-like LOC100912405 -39.71 7.61E-09 
DExD-box helicase 39B Ddx39b -16.06 3.31E-19 
Cytochrome P450, subfamily 2, 
polypeptide 11 Cyp2c11 -14.47 2.52E-06 
SH3 and cysteine rich domain 3 Stac3 -13.71 6.50E-06 
Tectorin beta Tectb -12.29 0.00025377 
Ras homolog family member U Rhou -10.34 7.66E-10 
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Table 2.4.4. Top 10 up- and down-regulated genes In PCK rats at PND 90. 
 
Gene Name Gene Symbol Fold Change q-value 
Up-regulated Genes 
Regenerating family member 3 beta Reg3b 11396.22 1.37E-32 
Interferon-inducible GTPase 1-like LOC100910934 8275.89 4.22E-07 
LY6/PLAUR domain containing 8 Lypd8 3642.45 1.26E-18 
Serine peptidase inhibitor, Kazal type 
1 Spink3 2016.91 5.84E-20 
Leukocyte elastase inhibitor A-like LOC100911107 1557.14 6.02E-38 
TEA domain transcription factor 4 Tead4 781.09 1.21E-29 
Lipocalin 2 Lcn2 146.66 2.79E-20 
Family with sequence similarity 111 Fam111a 106.52 2.26E-49 
Membrane spanning 4-domains A18 Ms4a18 65.89 1.07E-13 
Similar to interferon-inducible 
GTPase RGD1309362 60.81 2.09E-08 
Down-regulated Genes 
SH3 and cysteine rich domain 3 Stac3 -982.80 6.32E-21 
Similar to RIKEN cDNA 1700028P14 RGD1560242 -382.83 4.97E-18 
ATP binding cassette subfamily G 
member 8 Abcg8 -139.79 4.07E-34 
ATP binding cassette subfamily G 
member 5 Abcg5 -41.83 3.17E-29 
Hydroxy-delta-5-steroid 
dehydrogenase LOC100911154 -34.57 1.24E-07 
Carbonic anhydrase 3 Car3 -34.39 1.50E-08 
Major urinary protein 4 Mup4 -24.26 0.000915635 
Small nucleolar RNA 
SNORD113/SNORD114 family SNORD113 -16.77 0.003332349 
Carboxypeptidase A1 Cpa1 -15.28 5.27E-11 
Urinary protein 3-like LOC100912405 -13.54 1.06E-05 
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Identification of upstream regulators and canonical pathways in PCK rats.  
To further investigate the global gene expression data to identify key players, we 
performed an upstream regulator analysis using the Ingenuity Pathway Analysis (IPA) 
software. The upstream regulators were predicted based on the IPA database. 
Predicted upstream regulators at PND 15 are shown in Table 2.4.5. CTNNB1, MTPN, 
TCF7L2 and STAT5B were significantly activated (z ³ 2) in PCK rats, and CBX5 was 
significantly inhibited (z £ -2) in PCK rats. Interestingly, IPA analysis predicted activation 
of various members of STAT family of proteins from PND 20 to PND 90 (Table 2.4.6 – 
2.4.8). Our data suggest that STAT3 was the most significantly activated upstream 
regulator at PND 90 (Table 2.4.8). Similarly, IPA predicted activation of myotrophin 
(MTPN), a protein involved in regulation of NF-kB activity at all time points studied.  The 
analysis showed predicted inhibition of HNF4a at PND 30 and 90 in PCK rats.  
IPA analysis was used to identify changes in canonical pathways (Figure 2.4.2). 
The top canonical pathways changed included LPS/IL-1 signaling at PND 20, 30 and 90 
where it was significantly upregulated at PND30 and 90 indicating ongoing inflammatory 
signaling in PCK rat livers. Consistent with this increased IL-8 signaling was also 
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Figure 2.4.2. Top five impacted pathways in PCK rats from at PND 15, 20, 30, and 
90. Blue bars indicate negative z score. Orange bars indicate positive z score. The 
orange line indicates ratio of genes in the network to total number of genes in the 







Functional analysis of transcriptomic data from PND 30 to PND 90 in SD and PCK 
rats. 
As we found the number of differentially expressed genes was highest at PND 90, 
we compared the gene changes from PND 30 to PND 90 in SD and PCK rats. In each 
genotype, we identified the differentially expressed genes from PND 30 to PND 90, and 
we used IPA to compare the activation/inhibition status of different canonical pathways 
(Figure 2.4.3A) and diseases and functions (Figure 2.4.3B) in PCK rats compared to SD 
rats. This analysis revealed significantly higher activation of genes associated with 
inflammation including NF-kB activation, B and T lymphocyte-associated pathways, 
increased oxidative signaling via iNOS, and acute phase response (Figure 2.4.3A, 
indicated by the red box). Similarly, Nrf-2 signaling was reduced in SD rats from PND 30 
to 90 but was significantly increased in PCK rats (Figure 2.4.3A, indicated by red asterisk). 
The disease and function analysis revealed overall decrease in expression of genes 
associated with tumor growth and cell proliferation in SD rats from PND 30 to 90, and an 
increased activation of immune-associated functions in PCK rats from PND 30 to PND 90 
(Figure 2.4.3B, indicated by the red box). Interestingly, the genes associated with fibrosis 
were further inhibited in PCK rats compared to SD rats from PND 30 to PND 90 (Figure 







Figure 2.4.3. Comparison analysis between Sprague Dawley (SD) and PCK rats 
from PND 30 to PND 90. Hierarchical clustering analysis for pathways and disease and 
function. A dendrogram (tree graph) shows the grouping of the canonical pathways (A) 
and diseases and function (B) based on the similarity between them. Absolute z score 
cutoff is 2.  
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Identification of transcriptional regulators of the ‘pathogenic triumvirate’.  
 We proposed that a ‘pathogenic triumvirate’ consisting of cyst growth, 
inflammation, and fibrosis is the central regulator of CHF/ARPKD (Jiang et al. 2016). 
Therefore, we categorized the IPA-predicted transcriptional regulators based on their 
potential roles in each component of the ‘pathogenic triumvirate’ (Figure 2.4.4). In 
addition, we found several transcriptional regulators related to liver development, such 
as HNF4α, inhibition of which may cause an impaired liver development (Figure 2.4.4). 
Taken together, our data suggest that in addition to the components of the ‘pathogenic 
triumvirate’ that contribute to the progression of CHF/ARPKD, liver development and 








Figure 2.4.4. Schematic diagram showing molecular factors regulating 
pathogenesis of CHF/ARPKD. Based on the Ingenuity Pathway Analysis (IPA) 
knowledge base, transcription factors predicted by IPA are categorized into: cyst growth 
(cell proliferation), inflammation, and fibrosis. Transcription factor HNF4A not originally 
considered in the context of the ‘pathogenic triumvirate’ is now included to acknowledge 











CHF/ARPKD is a life-threatening genetic disease with distinct clinical features. 
Although the phenotypes of CHF/ARPKD are well-characterized, the mechanisms 
driving these phenotypes in CHF/ARPKD are still unknown. To define these 
mechanisms, we performed RNA-Seq analysis in SD and PCK rats at various time 
points to compare the gene expression alterations associated with mutation in gene 
PKHD1. Our data suggest that as the disease develops, there is an increased 
divergence from the normal phenotype. We also identified several canonical pathways 
and upstream regulators impacted by the disease.  
Among the top upregulated genes in PCK rats, Tead4 is consistently upregulated 
from PND 15 to PND 90. TEADs are important transcription factors of the Hippo 
signaling pathway. By partnering with Yes-associated protein (YAP), they activate the 
downstream targets of the pathway involved in cell proliferation, cell growth, planar cell 
polarity, and cell death (Vassilev et al. 2001, Zhao et al. 2007, Happe et al. 2011, Wu et 
al. 2013). Our previous study suggests that YAP is activated in cystic cholangiocytes 
from PCK rats and ARPKD patients. Inhibition of YAP activity with verteporfin, a YAP-
TEAD inhibitor, decreased cystic cholangiocyte proliferation in vitro (Jiang et al. 2017). 
Consistently, Ctgf, the YAP-TEAD target gene, is one of the top ten upregulated genes 
in PCK rats at PND 15, and its transcription level is still increased from PND 20 to PND 
90 (data not shown). Connective tissue growth factor (CTGF) is a matricellular protein 
that plays a central role in tissue remodeling (Lipson et al. 2012). CTGF expression can 
be induced in pathophysiological conditions, and it induces formation of myofibroblasts 
from different cell types, such as stellate cells (Paradis et al. 2002), epithelial cells 
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(Gore-Hyer et al. 2002), resident fibroblasts (Grotendorst et al. 2004), or recruited 
fibrocytes (Lee et al. 2015). CTGF expression is generally very low in normal liver, and 
its expression increases in liver fibrogenesis (Paradis et al. 1999). Inhibition of CTGF 
has been used as a therapeutic option in liver fibrosis (Li et al. 2006, Raghu et al. 2016, 
Sakai et al. 2017). These data indicate that the Yap-TEAD-CTGF axis could be a 
therapeutic target in CHF/ARPKD.  
Among the upstream regulators predicted by IPA, we found several STAT family 
members, including Stat3, Stat4, and Stat5b. Previous studies have shown strong 
activation of STAT3 regulated by polycystin-1 (PC-1), the gene product of PKD1 
(mutated in ADPKD) in cyst-lining epithelial cells in mouse and human ADPKD (Talbot 
et al. 2011). Further, treatment with STAT3 inhibitors decreased cell proliferation in 
human ADPKD cells, blocked renal cyst formation in a PKD mouse models and reduced 
cyst formation and growth in a neonatal PKD mouse model (Takakura et al. 2011). 
STAT6, another member of STAT family, has an increased activity in two murine PKD 
models, mediated by interleukins IL4 and IL13 (Olsan et al. 2011). Deletion of STAT6 in 
bpk/bpk, a model for PKD, resulted in less severe kidney disease and an improvement 
of kidney function. Pharmacological inhibition of STAT6 led to suppression of renal 
cystic growth, lower kidney weight and cystic index. (Olsan et al. 2011). Our 
observations indicate that other members of STAT family including STAT4 and 5B could 
also be involved in CHF/ARPDK pathogenesis.  
The IPA analysis predicted inhibition of Smad7, a negative regulator of 
transforming growth factor b (TGF-b) signaling, in PCK rats at PND 30 and PND 90. 
Inhibition of SMAD7 suggests an increased activation of the TGF-b signaling pathway, 
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which may further contribute to myofibroblast activation and fibrosis. The anti-fibrotic 
role of SMAD7 has been shown in multiple models of liver fibrosis including the CCl4-
induced liver fibrosis (Hamzavi et al. 2008), bile duct ligation, isolated primary hepatic 
stellate cells, (Dooley et al. 2003) and also in the unilateral ureteral obstruction (UUO)-
induced renal fibrosis (Terada et al. 2002). All of these studies suggest that inhibiting 
TGF- β signaling through activating Smad7 can be a potential therapeutic tool in 
ARPKD.  
In addition to the upstream regulators that were already established in ADPKD, 
such as STATs and SMAD-TGFb signaling, we also found some upstream regulators 
unique in ARPKD. Mtpn (myotrophin) is a novel target predicted by IPA in ARPKD. 
Upstream analysis revealed that Mtpn was activated from PND 15 to PND 90, 
suggesting its role is critical in ARPKD pathogenesis. Interestingly, MTPN stimulates 
insulin exocytosis, and its function can be suppressed by microRNA-375 (miR-375) 
(Poy et al. 2004), which is critical in maintenance of normal glucose homeostasis, 
regulation of insulin secretion and pancreatic a- and b-cell turnover in response to 
increasing insulin demand in insulin resistance (Poy et al. 2004, Poy et al. 2009). 
Interestingly, enhanced glycolysis, defective glucose metabolism, insulin resistance, 
and hyperinsulinemia have been reported in ADPKD patients (Vareesangthip et al. 
1997, Rowe 2013). Our studies have identified Mtpn as a novel therapeutic target in 
CHF/ARPKD, which may correct the metabolic disorder inherent in the pathogenesis.  
We also found that Hdac5, a histone deacetylase, was inhibited in PCK rats at 
PND 90. HDAC5, a class II HDAC, is generally associated with closed chromatin and 
represses gene expression through deacetylation of histones (Taunton et al. 1996, 
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Kadosh et al. 1997, Rundlett et al. 1998). HDAC5 is a negative regulator of 
angiogenesis, and silencing of HDAC5 increases the expression of fibroblast growth 
factor 2 (FGF2) and angiogenic guidance factors, including Slit2 (Urbich et al. 2009). 
Slit2 promotes angiogenesis by upregulating Robo1 and activating the vascular 
endothelial growth factor receptor 2 (VEGFR2)- extracellular signal-related kinase 1/2 
(ERK1/2) pathway (Li et al. 2015). Therefore, inhibited activity of HDAC5 indicates that 
angiogenesis may be increased in PCK rats, and its increase is possibly related to 
pathogenesis of CHF/ARPKD. This is consistent with a role for ‘pathologic’ 
angiogenesis associated with liver fibrosis and cirrhosis in response to increasing portal 
hypertension; this is a common feature associated with CHF/ARPKD(Medina et al. 
2003, Ni et al. 2017). 
Finally, our studies revealed inhibition of Hnf4a, the master regulator of hepatic 
differentiation in CHF/ARPKD. HNF4A plays a critical role in liver development and 
hepatocyte differentiation. In fact, HNF4A is absolutely essential in differentiation of 
hepatocytes from hepatoblasts and its downregulation results in increased cell 
proliferation and cancer in the liver (Walesky et al. 2013, Walesky et al. 2015). A 
detailed analysis of Hnf4a target genes showed decline in several cytochrome P450 
family members (Cyp3a5, Cyp2c9, and Cyp2b6), transporters (Abcc2, Abcg5, Abcg8, 
Aqp8, and Slco1a1), and lipid metabolism (Acox2, Acsl1, Lipa, Pla2g4a, and Srebf1). 
These data, for the first time reveal that CHF/ARPDK is not only associated with 
increased cystogenesis, fibrosis, and inflammation but also with significant 
dysregulation in hepatocyte differentiation, which may further increase disease-
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associated morbidity. Further studies are needed to investigate the role of HNF4A in the 
disease and how it regulates the pathogenesis of CHF/ARPKD.  
In conclusion, gene expression changes in CHF/ARPKD determined by RNA-
Seq analysis provide a detailed map of significantly altered genes, signaling pathways, 
and upstream regulators that are dysregulated in CHF/ARPKD. Our findings provide 
insight into the molecular drivers of CHF/ARPKD, and shed light on potential therapeutic 
























CHAPTER III: THE ROLE OF MAST CELLS IN CONGENITAL HEPATIC 









This chapter is adapted from Jiang L, P. P. Fang, S. Septer, U. Apte and M. T. 
Pritchard, “Inhibition of mast cell degranulation with cromolyn sodium exhibits organ-
specific effects in polycystic kidney (PCK) rats,” Int. J. Toxicol, 2018, Manuscript 








Autosomal recessive polycystic kidney disease (ARPKD) is a monogenic disease 
characterized by development of hepatorenal cysts, pericystic fibrosis, and 
inflammation. Previous studies show that mast cell (MC) mediators such as histamine, 
induce proliferation of cholangiocytes. We observed robust MC accumulation around 
liver cysts, but not kidney cysts, in polycystic kidney (PCK) rats (an animal model of 
ARPKD). Therefore, we hypothesized that MCs contribute to hepatic cyst growth in 
ARPKD. To test this hypothesis, we treated PCK rats with one of two different mast cell 
stabilizers, cromolyn sodium (CS) or ketotifen. CS treatment decreased MC 
degranulation in liver and reduced serum tryptase (a MC granule component). 
Interestingly, we observed an increase in liver/body weight ratio after CS treatment 
paralleled by a significant increase in individual cyst size. Hepatic fibrosis was not 
affected by CS treatment. CS treatment increased hepatic cyst wall epithelial cell 
(CWEC) proliferation and decreased cell death. Ketotifen treatment also increased 
hepatic cyst size. In vitro, CS treatment did not affect proliferation of isolated hepatic 
CWECs from PCK rats. In contrast, CS decreased the kidney/body weight ratio 
paralleled by a significant decrease in individual cyst size. The percentage of 
kidney/body weight ratio was strongly correlated with serum renin (a MC granule 
component). Ketotifen did not affect kidney cyst growth. Collectively, these data suggest 
that CS treatment affects hepatic and renal cyst growth differently in PCK rats. 
Moreover, CS may be beneficial to renal cystic disease, but it may exacerbate hepatic 





Congenital hepatic fibrosis (CHF) associated with autosomal recessive polycystic 
kidney disease (ARPKD) is a serious hepatobiliary disease for which no curative 
pharmacologic treatments exist (Dell 2011). Dysfunctional cholangiocyte cilia, due to 
mutations in PKHD1 and production of aberrant fibrocystin protein, are found in PCK 
rats, suggesting a possible role for disease pathogenesis (Onuchic et al. 2002, Ward et 
al. 2002). Thirty percent of neonatal CHF/ARPKD patients succumb to disease due to 
pulmonary hypoplasia secondary to grossly enlarged, cystic kidneys (Zerres et al. 
1998); those that survive the perinatal period may be plagued by recurrent episodes of 
acute cholangitis, severe portal hypertension and development of esophageal varices 
due to the progression of pericystic fibrosis. Adult CHF/ARPKD patients’ conditions are 
often further complicated due to development of biliary malignancies (Roy et al. 1997, 
Zerres et al. 1998). 
Previous research has identified several pathways which contribute to cyst wall 
epithelial cell (CWEC) proliferation and pericystic fibrosis in CHF/ARPKD. In CWECs, 
these mechanisms include reduced intracellular calcium, increased cAMP production 
and cAMP-mediated signaling, and increased production of pro-proliferative cytokines 
including IL6, EGF, VEGF and IGF-1 (Nichols et al. 2004, Masyuk et al. 2006, Masyuk 
et al. 2015). Therapeutic interventions targeting these pathways attenuate disease 
progression (Masyuk et al. 2015). In addition, pericystic fibrosis was reduced in 
polycystic kidney (PCK) rats after treatment with pioglitazone, a PPARγ agonist (Blazer-
Yost et al. 2010). Increased activation of the renin and angiotensin-converting enzyme 
system in PKD, consistent with severe portal hypertension which occurs in CHF/ARPKD 
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patients, is attenuated after treatment with telmisartan, an angiotensin receptor blocker 
(Yoshihara et al. 2013). However, even with these advances in our understanding of 
disease pathogenesis, pharmacologic interventions for CHF/ARPKD patients have not 
lead to significant improvements in patient outcome. Indeed, transplant remains the only 
cure for this disease.  
Mast cells (MCs) are components of the innate immune system with a broad 
range of effector activity (Urb et al. 2012). They synthesize and store many molecules 
including chymase, tryptase, and histamine, and renin in large cytoplasmic granules 
which they release during tissue injury and in response to other stimuli (Metcalfe et al. 
1997). MC produce a diverse array of cytokines, chemokines and growth factors 
including IL6 and VEGF (Kruger-Krasagakes et al. 1996, Boesiger et al. 1998). In 
addition to their well-known roles in allergy (Borish et al. 1992), MCs also exhibit 
profibrotic activity (Overed-Sayer et al. 2013) as well as growth-promoting activity for 
cholangiocytes after bile duct ligation in rats and mice (Hargrove et al. 2016, Hargrove 
et al. 2017). MCs are also associated with human liver disease (Francis et al. 2010). 
They are increased in the portal area of cirrhotic patients (Armbrust et al. 1997) and are 
considered pathogenic in human cholangiocarcinoma (Terada et al. 2000). An abundant 
literature suggests that MCs are associated with inflammatory and fibrotic disease 
(Overed-Sayer et al. 2013). Further, MCs are found surrounding the human biliary tree 
and the number of MCs increases in the liver in ARPKD patients (Ozaki et al. 2005). 
MCs also participate in the pathogenesis and progression of biliary disease in other 
animal models (Farrell et al. 1995, Ishii et al. 2005). However, no studies have explored 
the role of MCs in CHF/ARPKD. Here, we sought to test the hypothesis that MCs are 
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involved in the progression of CHF/ARPKD and are the common link between a 
triumvirate of pathogenic mechanisms (inflammation, proliferation and fibrosis (Jiang et 
al. 2016) involved in this disease.  
 
 
3.3 MATERIALS AND METHODS 
Animals 
Polycystic kidney (PCK, an orthologous model of human ARPKD) rats and 
normal Sprague-Dawley (SD) rats were obtained from Charles River Laboratories 
(Kingston, NY). Pkhd1LSL(−)/LSL(−) mice (an orthologous mouse model of human ARPKD) 
were a kind gift from Dr. Christopher J. Ward (University of Kansas Medical Center, 
KUMC) (Bakeberg et al. 2011).Animal treatment was approved by and performed in 
accordance with the Institutional Animal Care and Use Committee at KUMC.  
 
Treatments and Tissue Collection  
PCK rats were injected i.p. with saline or cromolyn sodium (CS, 50 mg/kg/day 
(Hei et al. 2007)) or ketotifen fumarate (1mg/kg/day) from postnatal day (PND) 15 to 
PND 30. CS and ketotifen were purchased from Sigma-Aldrich (St. Louis, MO). The 
treatment period was chosen based on the starting time point of MC infiltration in PCK 
rats (PND 15, Figure 1B) and the observed development of cysts and fibrosis from our 
earlier work (Jiang et al. 2017).  Rats were euthanized at PND 31. Pkhd1LSL(−)/LSL(−) mice 
were injected with saline or CS from PND 30 to PND 45. The treatment period was 
chosen based on the initiation of observable cysts and fibrosis in the liver. Liver, kidney, 
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and plasma were collected for further analysis as previously described (Deshpande et 
al. 2016).  
 
Histological Analysis 
Liver and kidneys were preserved in 10% buffered formalin, embedded in 
paraffin, and stained with hematoxylin and eosin (H&E). Average cyst size per liver 
section was calculated as the ratio of cystic area to the number of cysts. Cell death was 
assessed by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) 
staining using the In Situ Cell Death Detection Kit, TMR red (Roche Applied Science, 
Indianapolis, IN). Ki67 staining was performed on frozen sections (5 μm thick) as 
described before (Deshpande et al. 2016). ImageJ was used to quantify TUNEL staining 
and Ki67 staining by a blinded individual. For TUNEL staining, data were expressed as 
percentage of TUNEL positive cyst wall epithelial cells (CWECs) over total number of 
CWECs. For Ki67 staining, data were expressed as percentage of Ki67 positive CWECs 
for the liver, or non-CWECs for the kidney over total number of cells counted.  
 
Sirius red staining  
Formalin-fixed, paraffin-embedded (5 μM) liver sections were stained with 0.1% 
Sirius red solution as previously described (McCracken et al. 2016). All images were 
taken at 100x magnification with an Olympus BX51 microscope with an Olympus 
BH2RFLT3 burner and Olympus DP71 camera operated by DP Controller software 
(Olympus, Waltham, MA). Five non-overlapping images were acquired per liver section. 
One liver section per rat in each experimental group was photographed (n = 4-6 rats per 
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group). ImageJ was used to quantify the area of positive staining and intensity of that 
staining above an arbitrary threshold which remained constant for all images. 
 
Toluidine blue staining 
Toluidine blue staining was performed on formalin-fixed, paraffin-embedded (5 
μM) liver sections as described by Kennedy et al. (Kennedy et al. 2014). Briefly, liver 
sections were deparaffinized, rehydrated, and stained with toluidine blue working 
solution (pH 2.0-2.5). After staining, 200X images were taken using an Olympus DP71 
camera and later quantified by ImageJ using a constant threshold to differentiate “non-
degranulated” MCs from “degranulated” MCs, based on intensity of purple staining. A 
“degranulated” MC can be identified by loss of granule staining and visible release of 
granules. A “non-degranulated” MC maintains intact cell structure and retains intense 
granule staining. Total MC number was counted manually using the “Cell Counter” 
function from ImageJ. MCs above threshold were counted as “non-degranulated”. The 
number of “degranulated MC” was calculated by subtracting “non-degranulated” MC 
number from total MC number. All images were coded and analyzed by a blinded 
observer.  
 
RNA isolation, cDNA synthesis and real-time PCR 
Total RNA was isolated from RNAlater-stabilized tissue using an RNeasy Mini Kit 
(Qiagen, Valencia, CA). Four micrograms of RNA were reverse transcribed into 
complementary DNA (cDNA) using a Retroscript kit (Life Technologies/Ambion, Grand 
Island, NY). SYBR green (Universal Super Mix, BioRad, Hercules, CA) was used for 
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real-time PCR. Results were calculated using 2−ΔΔCt method. The data were expressed 
as fold change over saline-treated animals. 18S was used as the housekeeping gene 
and did not differ between treatment groups or genotypes. Primers utilized in this study 
are found in Table 3.3.1.  
 




Source Forward primer Reverse primer 
Cma1 NCBI CACTGTGCAGGACGGTCTAT TTGAAGTTGGCCGAGAGTGG 
Tpsab (Nakano et al. 2012) ACATCTGAGTGTTGCGCTGAAGCA CCCAACAGGTTGTGGTGTGCAGAAT 
Fcer1I NCBI GCTACCACTGCACAGGCTAT AACCCAGTGTCCACAGCAAA 
Acta2 (Vickers et al. 2004) AGCTCTGGTGTGTGACAATGG GGAGCATCATCACCAGCAAAG 
Col1a1 (Pritchard et al. 2010) TGAGCCAGCAGATTGAGAAC TGATGGCATCCAGGTTGCAG 
Hrh1 NCBI CAGACCTGATTGTAGGGGCAG CATAGAGAGCCAAAAGAGGCAG 
Hrh2 NCBI CCCAATGGCACGGTTCATTC GCCGACGATTCAAGCTGACA 
F2rl1 NCBI AGTCCGTCATGGCTTTGTCA CTCGCCTCTGCGGTTCTGTG 
 
 
Serum histamine and tryptase measurement  
Histamine release was measured in serum by histamine enzyme-linked 
immunosorbent assay (EIA) kits following the manufacturer’s instruction (Cayman 
Chemical, Ann Arbor, MI). Tryptase release was measured in serum by rat tryptase 
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(TPS) ELISA kit (Neo Scientific, Cambridge, MA). Renin release was measure in serum 
by rat renin-1 ELISA kit (RayBiotech, Norcross, GA). 
 
Total collagen calculation by hydroxyproline assay 
Hydroxyproline level was measured in liver as described by Reddy and 
Enwemka (Reddy et al. 1996). Brielfly, 10 mg liver tissue was weighed and subjected to 
digestion in 12 N hydrochloric acid (100 µl) and water (100 µl) at 120 °C for 3h. The 
samples were vortexed every 30 – 40 min during digestion to achieve complete 
homogenization. The supernatant was collected following centrifugation at 10,000 x g 
for 10 min. Samples were incubated with chloramine T (100 µl) at room temperature for 
25 min. Ehrlich’s reagent (100 µl) was added and the samples were incubated at 60°C 
for 35 min. Absorbance was measured at 550 nm. Hydroxyproline concentration was 
calculated using a standard curve. The amount of collagen was estimated by dividing 
the hydroxyproline concentration by 12.5 % as previously shown (Reddy et al. 1996).  
 
CWEC isolation and cell proliferation assay 
CWECs from PCK rats were isolated as described by LaRusso et al. and Jiang et 
al (Muff et al. 2006, Jiang et al. 2017). Briefly, the biliary tree was isolated following liver 
perfusion at 37oC. The biliary tree was then cut into small pieces and digested with 
Modified Eagle’s Medium containing 25 mM HEPES (Sigma-Aldrich), 10 mg 
hyaluronidase (Sigma-Aldrich), 8 mg collagenase P (Roche, Indianapolis, IN), and 6 mg 
DNase (Sigma-Aldrich) for 45 min in a 42°C water bath. The tissue pieces were then 
washed and cultured in collagen-coated plates. After 2-3 days of culture, proliferating 
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cysts were digested and CWEC plated as a monolayer. A cell proliferation assay was 
performed as described by Yamaguchi et al. (Yamaguchi et al. 2006). In brief, cells 
were treated with CS (10, 25, 50, and 100 μM) for 48h. Cell proliferation was 
determined based on the production of formazan using CellTiter 96 Aqueous One 
Solution Cell Proliferation Assay (Promega). The amount of formazan is directly 
proportional to the living cell number in culture.  
 
Statistics 
Results are represented as mean ± standard error of mean. Student’s t-test was 
used to calculate differences between two groups. One-way ANOVA was used for data 
in Figure 3.4.9A to determine statistical differences. Two-way ANOVA was used for data 
in Figure 3.4.1 B-E and Figure 3.4.2B-C to determine statistical differences. Post-hoc 
pairwise comparisons with multiple testing adjustments were completed using Tukey’s 
method for all data analyzed by ANOVA. A Pearson’s correlation was done to determine 
the relationship between two independent variables (Figure 3.4.12B). In each case, 
statistical significance was defined as p < 0.05.  
 
3.4 RESULTS 
Mast cells (MC) infiltrate the pericystic area of PCK rats.  
To determine if MC infiltration was increased in PCK rats, we stained liver 
sections from SD and PCK rats at PND 15, 20, 30 and 90 using toluidine blue, a 
histological stain which stains MC granules dark purple (Leclere et al. 2006) (Figure 
3.4.1A). The number of MCs was low in both SD and PCK rats at PND 15 and PND 20. 
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MC infiltration in PCK rats was increased at PND 30, and the number was significantly 
greater than that in SD rats. MC number did not increase further in either strain at PND 
90 (Figure 3.4.1B). To confirm the presence of MCs at the transcript level, we 
performed real time PCR to measure MC-specific target gene expression. Chymase 
(Cma1) and tryptase (Tpsab), two MC serine proteases, and Fce receptor I alpha 
(Fcer1a), the receptor which binds IgE on MCs (Kinet 1999), were all increased in livers 
from PCK rats when compared to SD rats from PND 15 – 90 (Figure 3.4.1C, D, and E). 
By PND 90, the transcripts for Cma1 declined relative to their levels at PND 30 in PCK 
rats (Figure 3.4.1C). Transcripts for Tpsab and Fcer1a remained elevated even at PND 
90 (Figure 3.4.1D and E).  
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Figure 3.4.1. Mast cell infiltration in SD and PCK rat livers. (A) Representative 
images of toluidine blue stained livers from SD and PCK rats from postnatal day (PND) 
0 to PND 90. Images were taken at 100X magnification. (B) Quantification of mast cell 
(MC) number over time. (C-E) MC-associated gene expression, Cma1(C), Tpsab (D), 
and Fcer1a (E)were measured by real-time PCR in SD and PCK rat livers from PND 0 
to PND 90. N=3-4 rats per group. *, P<0.05 between genotypes at the indicated time 
point. #, P<0.05 compared to previous time point within a genotype. 
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Evaluation of MC degranulation and granule-associated receptors in PCK rats.  
Degranulation is one mechanism by which MC can promote cell proliferation, 
inflammation, and fibrosis (Kondo et al. 2001, Amin 2012, Kennedy et al. 2014).  
Therefore, we next sought to determine whether or not the MCs found in livers from 
PCK rats were degranulated. First, we used toluidine blue to assess granule content in 
hepatic mast cells. A threshold differentiating a “non-degranulated” MC from a 
“degranulated” MC was set based on morphological differences described in the 
“method section”. Using this objective approach, the number and percent of non-
degranulated vs degranulated MCs was determined in livers from PCK rats. We found 
that the number and percent of degranulated MCs was greater at PND 30 than PND 20. 
The number of degranulated MCs did not change from PND 30 to PND 90, and the 
percent of degranulated MCs at PND 90 was not different than that found at PND 20 
(Figure 3.4.2B, C). We further evaluated the expression of two histamine receptors, 
H1R (Hrh1) and H2R (Hrh2), using biliary tree samples from SD and PCK rats. Our data 
suggest that histamine receptor expression (Hrh1 and Hrh2) did not differ between SD 
and PCK rats (Figure 3.4.2D, E). Interestingly, protease-activated receptor 2 (PAR2, 
F2rl1), a tryptase receptor, was expressed significantly higher in PCK rat biliary trees 











































Figure 3.4.2. Evaluation of mast cell (MC) degranulation and granule-associated 
receptors in PCK rat livers. (A) Examples of a non-degranulated MC (red arrow head) 
and a degranulated MC (black arrow head). Image was taken at 200X magnification. (B) 
Number of degranulated MCs in PCK rat livers at postnatal day (PND) 20, PND 30, and 
PND 90. (C) Percentage of degranulated MC in PCK rat livers at PND 20, PND 30, and 
PND 90. N=3-4 rats per group. (D-E) Gene expression of histamine receptors, Hrh1 (D) 
and Hrh2 (E), in biliary tree samples from SD and PCK rats. (F) Gene expression of 
tryptase receptor, protease-activated receptor 2 (PAR2, F2rl1), in biliary tree samples 
from SD and PCK rats. *, P<0.05 between groups.  
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Inhibition of MC degranulation, in vivo, using cromolyn sodium and its impact on 
hepatic cyst growth and pericystic fibrosis.  
Cromolyn sodium (CS) is a MC stabilizer used to treat asthma (Herzig et al. 
1975, Murphy et al. 1987). It has also been used to prevent MC degranulation in rats 
after bile duct ligation (Kennedy et al. 2014), an experimental model of cholestasis in 
which histamine promotes the proliferation of cholangiocytes. Therefore, we treated 
PCK rats with CS (50 mg/kg /day) from PND 15 to PND 30 to determine if we could 
prevent MC degranulation and prevent growth of hepatic cysts. After 15 days of CS 
treatment, MC degranulation was attenuated relative to saline-treated controls (Figure 
3.4.3A). Quantification of the number of non-degranulated cells and degranulated cells 
indicated a 40% decrease in degranulated cells after CS exposure (Figure 3.4.3B). To 
further support these observations, we measured histamine and tryptase, two mast cell 
granule contents, in serum from rats treated with CS. While histamine levels, measured 
using a histamine EIA, did not differ between saline and CS-treated rats (Figure 3.4.3C), 
levels of tryptase, as measured using a tryptase ELISA, were reduced (Figure 3.4.3D). 
Next, we evaluated the impact of CS exposure on hepatic cysts in PCK rats. 
Surprisingly, CS exposure increased cyst size determined by histological assessment of 
H&E staining (Figure 3.4.4A). This was reflected in an ~5% increase in the liver to body 
weight ratio in saline vs CS-treated rats (Figure 3.4.4B), as well as by a morphological 
analysis of individual cyst size which was also increased after CS exposure (Figure 
3.4.4C). Next, we wanted to elucidate the mechanism responsible for the increase in 
cyst size found in CS-treated PCK rat livers. In other words, an increase in cyst size 
could be due to an increased cyst wall epithelial cell (CWEC) proliferation and a 
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decrease in CWEC death. To determine if the increase in cyst size was due to an 
increase in CWEC proliferation, we performed Ki67 staining of liver sections from PCK 
rats. Ki67 staining indicated a 90% increase in CWEC proliferation after CS treatment 
compared to proliferation found in saline-treated PCK rats (Figure 3.4.5A, C). Next, we 
used TUNEL staining to determine whether CS exposure altered CWEC cell death. We 
found a trend to a greater number of TUNEL-positive nuclei in livers from saline-treated 
PCK rats when compared to CS-treated rats (Figure 3.4.5B, D).   
Given that both cyst size and number increase in PCK rats from PND 0 to PND 
90 and that fibrosis increases in parallel with cyst expansion (Jiang et al. 2017), we 
predicted that the increased cyst size observed in CS-treated PCK rats would be 
associated with increased pericystic fibrosis. To evaluate fibrosis, we used Sirius red 
staining and a biochemical assay to estimate the amount of collagen found in livers from 
control and CS-treated PCK rats. Morphometric analysis of Sirius red-positive staining 
indicated that CS treatment did not increase liver fibrosis when compared to saline-
treated PCK rats (Figure 3.4.6A, B, and C). Consistently, hydroxyproline analysis 
revealed that collagen content was the same in PCK rats, regardless of treatment 
(Figure 3.4.6D). Levels of α-smooth muscle actin (αSMA/Acta2), a marker for 
myofibroblasts (Frangogiannis et al. 2000), and type I collagen (Col1a1) were not 





Figure 3.4.3. Effect of cromolyn sodium (CS) on mast cell (MC) degranulation in 
PCK rat livers. (A) Representative images of toluidine blue stained liver sections from a 
saline treated PCK rat and a CS treated PCK rat. Images were taken at 200X 
magnification. (B) Percentage of degranulation of MC in saline and CS treatment group. 
(C-D) Serum level of histamine (C) and tryptase (D) in saline and CS treatment group. 








Figure 3.4.4. Effect of cromolyn sodium (CS) on livers from PCK rats. (A) 
Representative histology of hematoxylin and eosin (H&E) stained liver slides from saline 
and CS treated PCK rats. Asterisks (*) indicate cysts. Images were taken at 100X 
magnification. (B-C) Ratio of liver to body weight expressed as a percent of body weight 





Figure 3.4.5. Evaluation of cell proliferation and cell death following cromolyn 
sodium (CS) treatment. (A-B) Representative images of Ki67 (A) and TUNEL (B) 
stained liver sections from saline and CS treated PCK rats. DAPI was used to visualize 
nuclei. Images were taken at 200X magnification. Asterisks (*) indicate cysts. Arrow 
heads indicate Ki67 (A) or TUNEL (B) positive cells. (C-D) Percentage of Ki67 (C) and 
TUNEL (D) positive cyst wall epithelial cells (CWECs) over total CWECs. N=4 rats per 




Figure 3.4.6. Evaluation of liver fibrosis following cromolyn sodium (CS) 
treatment in PCK rats. (A) Representative images of Sirius red stained liver sections 
from saline and CS treated PCK rats. Images were taken at 100X magnification. 
Asterisks (*) indicate cysts. (B-C) Quantification of Sirius red staining by measuring 
percentage of Sirius red positive area (B) and intensity (C) in saline and CS treated 
PCK rats. (D) Hepatic hydroxyproline concentration was determined using a 
biochemical assay from which approximate collagen content was calculated. (E-F) 
Hepatic fibrotic marker transcript Acta2 (E) and Col1a1 (F) were measured using real-
time PCR. The data are expressed as fold change over saline. N=3-7 rats per group. *P 
< 0.05 between groups.  
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Impact of CS exposure on renal cyst growth and fibrosis indices.   
Because PCK rats exhibit both hepatic and renal cysts, we sought to determine if 
CS exposure increases renal cyst growth and fibrosis. First, we evaluated MC numbers 
in kidneys from PCK rats and found that MC number was limited in the kidney 
compared to the increased MC accumulation in liver (Figure 3.4.7A). CS treatment 
caused a reduction in kidney to body weight ratio (Figure 3.4.7B), and morphological 
analysis of cysts revealed that cystic area was reduced in kidneys from PCK rats 
treated with CS (Figure 3.4.7C). As expected, CS treatment of SD rats did not affect 
kidney to body weight ratio compared to saline treatment (Figure 3.4.7D).  
Evaluation of renal epithelial cell proliferation by Ki67 staining revealed that CS 
exposure suppressed proliferation only of non-cystic epithelial cells (i.e. cystic 
epithelium was Ki67 negative, p=0.0599, Figure 3.4.8A, C). TUNEL staining revealed a 
decrease in cyst epithelial cell death in kidneys from CS-treated PCK rats (Figure 
3.4.8B, D). Renal interstitial fibrosis in PCK rats is not evident until PND 70 (Lager et al. 
2001). Therefore, we analyzed Acta2 and Col1a1 transcripts as markers of early 
fibrogenic changes in the kidney. We found that these transcripts were reduced in 
kidneys from CS-treated PCK rats compared to kidneys from saline-treated PCK rats 






Figure 3.4.7. Effect of cromolyn sodium (CS) on kidney cyst growth in PCK rats 
and Pkhd1LSL(−)/LSL(−) mice. (A) Toluidine blue stained kidney section from a PCK rat. 
Image was taken at 400X magnification. Arrow heads indicate mast cells. (B) Ratio of 
kidney to body weight in PCK rats following saline or CS treatment expressed as a 
percent of body weight. *P < 0.05 between groups. (C) Representative images of 
hematoxylin and eosin (H&E) stained kidney sections from saline and CS treated PCK 
rats. Asterisks (*) indicate cysts. N=4-6 rats per group. (D) Ratio of kidney to body 
weight in SD rats following saline or CS treatment expressed as a percent of body 






















Figure 3.4.8. Evaluation of renal cell proliferation and cell death following 
cromolyn sodium (CS) treatment. (A-B) Representative images of Ki67 (A) and 
TUNEL (B) stained kidney sections from saline and CS treated PCK rats. DAPI was 
used to visualize nuclei. Images were taken at 200X magnification. Asterisks (*) indicate 
cysts. Arrow heads indicate Ki67 or TUNEL positive cells. (C-D) Percentage of Ki67 
positive non-cystic epithelial cells (C) and TUNEL-positive cyst wall epithelial cells over 
total number of cells counted. (E-F) Fibrotic marker transcript (E) Acta2 and (F) Col1a1 
were measured in PCK rat kidneys using real-time PCR. Data are expressed as fold 
change over saline. N=4 rats per group. *P < 0.05 between groups. 
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Evaluation of an off-target effect of CS on cyst growth.  
We performed three additional experiments to determine if CS had a direct effect 
on cyst growth, independent of its MC stabilization activity. First, in a previous study 
(Jiang et al. 2017), we optimized the isolation and culture of CWEC from PCK rats and 
found that they formed cytokeratin (CK) 19-postive colonies consistent with their 
cholangiocyte origin. Next, we exposed CWECs to increasing concentrations of CS, in 
vitro. We found that at CS did not increase CWEC proliferation (Figure 3.4.9A). 
Forskolin, a cAMP agonist, stimulates renal cystic epithelial cell proliferation in 
autosomal dominant polycystic kidney disease (ADPKD) through activating the B-Raf-
MEK-ERK pathway (Tesmer et al. 1997, Yamaguchi et al. 2000). In our study, forskolin 
treatment increased hepatic CWEC proliferation by 50% demonstrating that our CWEC 
were capable of proliferation, in vitro.   
To unequivocally prove that MCs have a direct effect on hepatic cyst growth in 
ARPKD, and that CS did not have an off-target effect on CWECs, we capitalized on an 
observation we made in mouse models of ARPKD since the mouse model of ARPKD 
did not show increased MC infiltration (Figure 3.4.9B). Therefore, in our second 
experiment, we exposed Pkhd1LSL(−)/LSL(−) mice to CS and evaluated hepatic cystic 
indices. Similar to PCK rats, Pkhd1LSL(−)/LSL(−) mice exhibited aggressive development of 
hepatic cysts and pericystic fibrosis by PND 30. However, toluidine blue staining 
demonstrated that MCs were not present in livers from Pkhd1LSL(−)/LSL(−) mice (Figure 
3.4.9B). Confident that these mice were effectively liver MC-deficient, we then exposed 
Pkhd1 mutant mice to CS and evaluated cyst growth and fibrosis using the same 
methods as performed for PCK rats. We found that CS treatment did not affect liver to 
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body weight ratios (Figure 3.4.9C), cyst size (Figure 3.4.9D), or fibrosis (Figure 3.4.9E, 
F). 
As a third approach to investigate if CS directly impacts cyst growth and fibrosis 
in ARPKD, we treated PCK rats with another MC stabilizer, ketotifen, from PND 15 to 
PND 30. Similar to what we found in CS-treated PCK rats, ketotifen treatment effectively 
inhibited MC degranulation compared to the saline-treated group (Figure 3.4.10A, B). 
We also measured tryptase level in serum, but we did not detect a significant difference 
between saline- and ketotifen-treated groups (Figure 3.4.10C). We evaluated hepatic 
cyst burden and fibrosis after ketotifen treatment and found that hepatic cyst size was 
significantly increased with no change in hepatic fibrosis (Figure 3.4.11A-D); renal cyst 
size did not change after ketotifen treatment (Figure 3.4.11E). 
Increased activity of renin-angiotensin-aldosterone system (RAAS) has been 
implicated in the pathogenesis of renal cysts in ADPKD and ARPKD (Graham et al. 
1988, Torres et al. 1992, Goto et al. 2010). To investigate if renin, a MC granule 
component, was responsible for the change of renal cyst size. We measured renin level 
in serum samples from SD rats and PCK rats treated with saline, CS, or ketotifen. We 
found that renin level in saline-treated PCK rats was significantly higher compared to 
SD rats (Figure 3.4.12A). Compared to saline treated PCK rats, CS treatment trended to 
decrease renin, but the decrease was not statistically significant. Ketotifen treatment 
had no impact on renin level compared to saline treated PCK rats (Figure 3.4.12A). 
Interestingly, the percentage of kidney/body weight ratio was strongly correlated with 























Figure 3.4.9. Effect of cromolyn sodium (CS) on isolated hepatic cyst wall 
epithelial cells (CWECs) and Pkhd1LSL(−)/LSL(−) mice. (A) Effects of different CS 
concentrations on CWEC proliferation. CWECs were treated with the indicated CS 
concentrations, vehicle, or forskolin (FSK, 5 µM). Each experiment was repeated three 
times (CWECs from 3 separate biliary trees from 3 separate rats isolated on 3 separate 
days). (B) toluidine blue stained liver section from a Pkhd1LSL(−)/LSL(−) mouse. Image was 
taken at 200X magnification. Asterisks (*) indicate cysts. *P < 0.05 compared to control. 
(C-D) Ratio of liver to body weight expressed as a percent of body weight (C) and 
average cyst size (D) in Pkhd1LSL(−)/LSL(−) mice treated with saline and CS. (E-F) 
Quantification of Sirius red stained liver sections by calculating percentage of Sirius red 
positive area (E) and measuring intensity of staining (F) per 100X magnification field. 




Figure 3.4.10. Effect of ketotifen on mast cell (MC) degranulation in PCK rats. (A) 
Representative images of toluidine blue-stained liver sections from a saline-treated PCK 
rat and a ketotifen-treated PCK rat. Images were taken at 200X magnification. (B) 
Percent degranulated MC after saline or ketotifen treatment. (C) Serum level of tryptase 






Figure 3.4.11. Evaluation of liver cysts and fibrosis following ketotifen treatment 
in PCK rats. (A) Representative images of Sirius red-stained liver sections from saline- 
and ketotifen-treated PCK rats. Images were taken at 100X magnification. Asterisks (*) 
indicate cysts. (B-C) Quantification of Sirius red staining by calculating percentage of 
Sirius red-positive area (B) and measuring intensity (C) in saline- and ketotifen-treated 
PCK rats. (D) Average cyst size after saline or ketotifen treatment. (E) Representative 
images of hematoxylin and eosin (H&E) stained kidney sections from saline and 
ketotifen treated PCK rats. Image was taken at 200X magnification. N=7-8 rats per 













Figure 3.4.12. Evaluation of the relationship between renin and kidney cyst 
growth. (A) Serum level of renin in SD rats, saline-treated PCK rats, cromolyn sodium 
(CS) -treated PCK rats, and ketotifen-treated PCK rats. N = 4 - 13 per group. *, P<0.05 
compared to SD. (B) Correlation between renin and percentage of kidney/body weight 
ratio in PCK rats. R = 0.9975, P < 0.05. (C) Working model: different mast cell (MC) 
granule components have different effects on liver vs. kidney in CHF/ARPKD. In liver 
samples from PCK rats, we observed an increased MC infiltration and increased 
expression of tryptase receptor (PAR2). Activation of PAR2 induces an increase in 
intracellular Ca2+ that prevents cyst expansion by limiting intracellular cAMP levels. 
Therefore, inhibition of tryptase release by mast cell stabilizing agents could prevent 
increases in intracellular Ca2+ levels, leading to a high intracellular cAMP, further 
exacerbating hepatic cyst expansion. Whether renin has an effect on liver cysts remains 
to be elucidated. In kidney, the pathogenic role for infiltrated MC is likely minimal since 
renal MC numbers are very low and restricted to connective tissue surrounding the 
kidney. However, as MC granules contain renin and the renin-angiotensin-aldosterone 
system promotes autosomal dominant polycystic kidney disease (Atlas 2007), inhibition 
of MC degranulation anywhere in the body could attenuate renin levels. Therefore, the 
reduction of renal cyst size we observed after stabilizing MCs could be due to a 
decrease in systemic renin and renin-mediated renal cyst expansion. Moreover, as 
renin also has pro-fibrotic effects, reduced renin levels due to MC granule stabilization 
could attenuate fibrogenic processes in liver or in kidney. 
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3.5 DISCUSSION 
ARPKD is a rare genetic disease accompanied by hepatorenal cysts and 
pericystic fibrosis (Gunay-Aygun et al. 2010, Gunay-Aygun et al. 2013). Previously, we 
hypothesized that the disease is regulated by a “pathogenic triumvirate” consisting of 
CWEC proliferation, fibrosis, and inflammation (Jiang et al. 2016). MCs are 
inflammatory cells found in a number of pathologies (Bachelet et al. 2006). In this study, 
we investigated the role of MCs in the progression of hepatorenal cyst growth and 
associated fibrosis in PCK rats. Our findings provide novel evidence to support the 
differential function that MCs have on cholangiocyte and renal epithelial cell proliferation 
in an animal model of ARPKD. Our study demonstrated that: (i) MCs infiltrated the 
pericystic areas of PCK rat liver but did not accumulate in the cystic regions of PCK rat 
kidney; (ii) increased MC infiltration correlated with increased expression of MC markers 
in PCK rat liver, and (iii) inhibition of MC degranulation promoted hepatic cyst growth 
but inhibited (CS), or did not alter (ketotifen), renal cyst growth in PCK rats.  
MCs function, in part, through the release of preformed mediators found in large 
cytoplasmic granules in a process called degranulation.  Granule contents include 
molecules such as histamine, proteases, and proinflammatory cytokines (Borish et al. 
1992).  Previous studies by Kennedy et al. suggest that histamine is the major MC 
granule component that stimulates cholangiocyte proliferation in bile duct ligated rats (a 
model of cholestasis) (Kennedy et al. 2014). To study MC degranulation in PCK rat 
livers, we quantified the number of degranulated MCs in PCK rats. Our data suggested 
that MC degranulation peaked at PND 30, in parallel with the peak of MC infiltration. By 
treating PCK rats with CS, a MC stabilizer, we found MC degranulation was significantly 
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inhibited in line with reduced serum tryptase level. Previous studies show that CS 
treatment decreases cholangiocyte proliferation and increases apoptosis in animal 
models of cholestasis and primary sclerosing cholangitis (Kennedy et al. 2014, Jones et 
al. 2016). In contrast, we saw a different effect of CS in our model where CS treatment 
increased hepatic cyst size by increasing CWEC proliferation and decreasing CWEC 
apoptosis. The CS-related enhancement of hepatic cyst growth was supported by 
several parameters including liver to body weight ratio, cyst size, CWEC proliferation, 
and cell death. Consistently, inhibiting MC degranulation with ketotifen also significantly 
increased hepatic cyst size. We excluded the direct effect of CS on hepatic cysts by 
incubating isolated CWECs with CS for 48 h (Figure 9A), supporting the idea that MCs, 
and not CS alone, limit hepatic disease in PCK rats.  
A previous study suggests that histamine from MCs stimulates cholangiocyte 
proliferation in a rat model of cholestasis (Kennedy et al. 2014), and inhibiting MC 
degranulation with CS inhibits cholangiocyte proliferation in that model. Those data 
suggest that histamine-histamine receptor interactions are critical for cholangiocyte 
proliferation. In our study, we examined the expression level of histamine receptors by 
real-time PCR using biliary tree samples from SD and PCK rats. We found that Hrh1 
and Hrh2 expression in PCK rats did not differ from SD rats, and there was no systemic 
decrease in serum histamine level after CS treatment. This suggests that histamine may 
not play a pathogenic role in ARPKD. However, we observed a decrease in serum 
tryptase level after CS treatment, and the mRNA for its receptor, PAR2, was expressed 
significantly higher in PCK rats compared to SD rats. Activation of PAR2 induces a rapid 
intracellular Ca2+ influx (Moormann et al. 2006) that acts as an antagonist of cyst 
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expansion by repressing B-Raf, a kinase upstream of the MEK-ERK pathways and 
reducing cAMP levels by activating PDE1, a Ca2+-dependent phosphodiesterase 
(Yamaguchi et al. 2004). It is plausible to speculate that reduction of tryptase by CS 
caused a decrease in Ca2+ level, which further exacerbated hepatic cyst expansion in a 
cAMP-depended fashion (Figure 3.4.12).  
Previous studies suggest that the renin-angiotensin-aldosterone system (RAAS) 
is upregulated in liver and kidney from PCK rats, and its activation is associated with 
hepatorenal cyst expansion and fibrosis (Goto et al. 2010, Goto et al. 2010). MCs are 
capable of synthesizing and releasing the active form of renin. Therefore, this extra-
renal renin production could further activate the RAAS (Silver et al. 2004). Consistent 
with previous studies, systemic renin was increased in PCK rats compared to SD rats, 
suggesting a role of renin in pathogenesis of ARPKD. Inhibition of MC degranulation 
with CS trended to reduce plasma renin levels in our study. We expected a decrease in 
liver fibrosis after CS treatment, but this did not happen. However, several mediators 
can promote fibrosis, so perhaps a reduction in renin did not attenuate fibrosis because 
other factors were still promoting fibrosis. For example, increased liver stiffness is a key 
factor driving the progression of fibrosis (Olsen et al. 2011). We observed an increase in 
hepatic cyst size after CS treatment which could have increased liver stiffness. 
Therefore, it is plausible to speculate that reduced renin levels in the context of 
increased liver stiffness prevented an attenuation of fibrosis after CS treatment.   
MCs are associated with a variety of renal diseases. Although MCs are found 
infrequently in normal kidneys, their number increases in the presence of renal injury 
(Holdsworth et al. 2008). In PCK rat kidneys, MC number did not increase even though 
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they develop renal cysts and interstitial fibrosis. Therefore, we speculate that MCs may 
not play a pathogenic role on renal cyst growth. It is already appreciated that RAAS 
activation contributes to the pathophysiology of ADPKD not only through the promotion 
of hypertension but also by directly stimulating the growth of renal cysts (Atlas 2007). 
Therefore, the beneficial effect of CS treatment on renal cyst reduction could possibly 
due to a decrease in serum renin level (Figure 3.4.12). As we expected, although the 
decrease of renin in CS-treated PCK rats was moderate, we showed a strong 
correlation between percentage of kidney/body weight ratio and renin. In contrast, 
ketotifen treatment didn’t affect renin level as we saw in the CS experiment. This may 
explain why we didn’t observe renal size change after ketotifen treatment. In addition to 
renin, serum tryptase was not significantly suppressed in PCK rats after ketotifen 
treatment, despite evidence for MC granule stabilization in ketotifen-treated rats. These 
data suggest that the strength of the MC stabilization differed between the two 
compounds. 
Compared to what we found in the liver, CS treatment caused a decrease in non-
cystic renal epithelial cell proliferation, suggesting that MC stabilization may delay 
formation of renal cysts. Interestingly, we also observed a decrease in cystic renal 
epithelial cell death after CS treatment to PCK rats. A previous study suggests that 
inhibiting apoptosis in a rat model of PKD effectively inhibits cystogenesis (Tao et al. 
2005). Whether a decrease in renal epithelial cell proliferation mediated by renin or 
other mediators or increase in cystic epithelial cell death is the driver or the outcome of 
cystogenesis in our study remains to be elucidated.  
 87 
Finally, a previous study suggests that activation of RAAS may lead to formation 
of interstitial fibrosis in kidney (Cao et al. 2001). Therefore, inhibiting renin release by 
CS treatment may contribute to a decrease in renal fibrosis. Although kidney fibrosis is 
not established at this time point in PCK rats, we did observe that Acta2 and Col1a1, 
two fibrotic genes, were reduced after CS treatment. This suggests reduced fibrogenic 
potential in the kidney. Further analysis is needed to determine if the decrease in fibrotic 
gene expression is due to a reduction in renal cyst size as discussed above for the liver, 
or an inhibition of RAAS activation.  
In summary, we have shown that MC number is increased in liver but not kidney 
in PCK rats, an animal model of CHF/ARPKD. Inhibition of MC degranulation with CS 
had differential effects on hepatic and renal disease in the PCK rat. These data 
indicated a protective role of MC in hepatic pathophysiology but a pathogenic role in 
renal pathophysiology. Moreover, this study also suggests that mechanisms driving 
cholangiocyte proliferation in animal models of other biliary diseases are not directly 
translatable to mechanisms which drive CWEC proliferation in CHF/ARPKD. Clinically, 
usage of CS may be beneficial to patients who only have renal cysts but should be 
prescribed with caution to patients with hepatic cysts. In the case of ARPKD where 
patients have both hepatic and renal cysts, CS should be avoided to prevent 
exacerbation of hepatic disease. However, perhaps CS’s reno-protective effects could 
be explored further and lead to kidney-targeted drug delivery approaches to achieve 
























CHAPTER IV: THE ROLE OF YAP IN CONGENITAL HEPATIC 










This chapter is adapted from Jiang, L., L. Sun, G. Edwards, M. Manley, Jr., D. P. 
Wallace, S. Septer, C. Manohar, M. T. Pritchard and U. Apte (2017). "Increased YAP 
Activation Is Associated With Hepatic Cyst Epithelial Cell Proliferation in ARPKD/CHF." 
Gene Expr 17(4): 313-326. doi: 10.3727/105221617X15034976037343 with permission 
from Cognizant, LLC; www.cognizantcommunications.com copyright.  
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4.1 ABSTRACT 
Autosomal recessive polycystic kidney disease/congenital hepatic fibrosis 
(CHF/ARPKD) is a rare but fatal genetic disease characterized by progressive cyst 
development in the kidneys and liver. Liver cysts arise from aberrantly proliferative 
cholangiocytes accompanied by pericystic fibrosis and inflammation. Yes associated 
protein (YAP), the downstream effector of the Hippo signaling pathway, is implicated in 
human hepatic malignancies such as hepatocellular carcinoma, cholangiocarcinoma, 
and hepatoblastoma, but its role in hepatic cystogenesis in CHF/ARPKD is unknown. 
We studied the role of the YAP in hepatic cyst development using polycystic kidney 
(PCK) rats, an orthologous model of ARPKD, and in human CHF/ARPKD patients. The 
liver cyst wall epithelial cells (CWECs) in PCK rats were highly proliferative and 
exhibited expression of YAP. There was increased expression of YAP target genes, 
Cyclin D1 and Ctgf (connective tissue growth factor), in PCK rat livers. Extensive 
expression of YAP and its target genes was also detected in human CHF/ARPKD liver 
samples. Finally, pharmacological inhibition of YAP activity with verteporfin and short-
hairpin (sh) RNA-mediated knockdown of YAP expression in isolated liver CWECs 
significantly reduced their proliferation. These data indicate that increased YAP activity, 
possibly through dysregulation of the Hippo signaling pathway, is associated with 







Polycystic kidney disease (PKD) is heritable genetic disorder characterized by 
the formation and growth of fluid-filled cysts in ductal structures, including the kidneys 
and liver.  Autosomal dominant PKD (ADPKD), the more common form of the disease 
(1 in 500 people affected), is caused by mutations in PKD1 or PKD2, which code for 
polycystin-1 and polycystin-2, respectively (Ward 1994, Burn et al. 1995, Mochizuki et 
al. 1996). Autosomal recessive PKD (ARPKD), a rare form of disease (1 in 20,000 
people affected), is caused by mutations in PKHD1, which encodes fibrocystin (Igarashi 
et al. 2002). All three proteins are localized to primary cilia on epithelial cells. However, 
it remains unclear how disruption of these ciliary proteins induces epithelial cyst 
formation (Turkbey et al. 2009, Lazaridis et al. 2015). The liver is the major extra-renal 
organ affected in PKD. In 60% of ADPKD and 100% of ARPKD patients, large fluid-filled 
cysts develop in the liver, resulting in hepatic enlargement, inflammation and fibrosis, 
which significantly contribute to the morbidity associated with PKD (Everson et al. 2004, 
Everson et al. 2008, Wen 2011). 
Hepatic cytogenesis and associated complications are especially problematic in 
ARPKD. ARPKD patients develop hepatic cysts surrounded by extensive pericystic 
fibrosis during the perinatal period and suffer from congenital hepatic fibrosis (CHF) 
(Everson et al. 2004, Everson et al. 2008, Wen 2011). CHF/ARPKD patients exhibit 
significant portal hypertension secondary to pericystic fibrosis. Recent studies have 
characterized CHF/ARPKD as a major pediatric liver disorder with significant mortality 
(Turkbey et al. 2009). Aside from symptom management, the only treatment option for 
CHF/ARPKD patients is liver and kidney transplantation.  
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The hepatic cysts in PKD are made up of epithelial cells which originate from 
dysgenesis of biliary epithelium (Masyuk et al. 2009). One of the main aspects of 
CHF/ARPKD pathogenesis is the aberrant proliferation of cyst wall epithelial cells 
(CWECs) (Masyuk et al. 2006, Lazaridis et al. 2015). The mechanisms responsible for 
CWEC proliferation remain unclear. Recent studies have shown that deregulation of the 
Hippo signaling pathway results in increased expression and activity of its downstream 
effector Yes associated protein (YAP), which is involved in a number of fibro-
proliferative hepatic disorders including hepatic fibrosis, hepatocellular carcinoma and 
cholangiocarcinoma (Camargo et al. 2007, Pan 2010, Li et al. 2012, Septer et al. 2012). 
When the Hippo signaling pathway is ‘on’, activation of LATS1/2 kinases directly 
phosphorylate YAP, which inhibits YAP nuclear translocation. When the Hippo signaling 
pathway is ‘off’, YAP is translocated to the nucleus and binds to different transcription 
factors to regulate target genes involved in cell proliferation, cell survival, and apoptosis 
(Di Cara et al. 2015, Yu et al. 2015). A previous study showed increased YAP activation 
in kidney cyst epithelial cells from ADPKD and ARPKD patients (Happe et al. 2011); 
however, the role of YAP in hepatic cyst development in CHF/ARPKD is not known. Our 
studies were undertaken to determine the role of YAP in liver CWEC proliferation with 
the use of human CHF/ARPKD liver tissues and animal models of CHF/ARPKD. 
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4.3 MATERIALS AND METHODS 
Animals  
Male and female polycystic kidney (PCK) rats and Sprague-Dawley (SD) rats 
(control strain for PCK) were purchased from Charles River and housed in an AAALAC-
approved vivarium at the University of Kansas Medical Center (KUMC). 
Pkhd1LSL(−)/LSL(−) mice on a C57BL/N background were a kind gift from Dr. Christopher J. 
Ward (KUMC); wild-type mice on the same genetic background purchased from Charles 
River (Wilmington, MA) were used for controls. All animal studies were approved by the 
KUMC Institutional Animal Care and Use Committee (IACUC) and were performed in 
accordance with IACUC guidelines. 
  
Tissue Harvest and Processing 
Rats (n=3-4 per time point) were euthanized under isoflurane anesthesia and 
livers were harvested at postnatal days 0, 5, 10, 15, 20, 30 and 90. Livers were 
processed for obtaining paraffin sections and frozen sections, total cell extracts and 
RNA as described before (Septer et al. 2012, Walesky et al. 2013). Body weights and 
liver weights were recorded at the time of euthanasia. 
  
Histopathological Analysis 
Formalin-fixed, paraffin-embedded liver sections were used for morphological 
analysis and immunohistochemical staining, and frozen liver sections were used for 
immunofluorescence staining. Cells were cultured on coverslips to appropriate density 
and fixed with 4% paraformaldehyde for immunofluorescence staining. Hematoxylin and 
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eosin (H&E) stained sections were used to determine the number of hepatic cysts. The 
source and details of primary antibodies used in these studies are as follows: 
proliferating cell nuclear antigen (PCNA, monoclonal antibody (mAb), clone PC10, Cell 
Signaling Technologies, Danvers, MA), phospho-YAP (Ser127)  (polyclonal antibody 
(pAb), cat# 4911, Cell Signaling Technologies), Cyclin D1 (mAb, clone 92G2, Cell 
Signaling Technologies), Ki 67 (pAb, cat# ab-15580, Abcam, Cambridge, MA), YAP 
(pAb, cat# 4912, Cell Signaling Technologies; cat# sc-101199, Santa Cruz 
Biotechnology, Santa Cruz, CA), Cytokeratin 19 (Ck19, pAb, cat# sc-33119, Santa Cruz 
Biotechnology), connective tissue growth factor (CTGF, pAb, cat# sc-14939, Santa Cruz 
Biotechnology), and β-actin (mAb, clone 13E5, Cell Signaling Technologies). Secondary 
antibodies for immunohistochemistry and immunofluorescence were purchased from 
Jackson Immunoresearch (West Grove, PA). Primary antibodies were used at a 
concentration of 1:100 (except PCNA, which was used at a concentration of 1:5000) 
and secondary antibodies were used at a concentration of 1:500. Micrographs were 
taken using an Olympus BX51 microscope with an Olympus DP71 camera. DP 
Controller software was used to acquire images at indicated magnifications (Olympus, 
Waltham, MA). 
  
RNA Isolation, cDNA Synthesis and Real Time PCR  
Total RNA was isolated from liver pieces and biliary trees as describe 
(Deshpande et al. 2016). Briefly, tissues (25-30 mg) were homogenized using an MP 
Biomedicals Fast Prep 24 bead homogenizer with lysing matrix D homogenization tubes 
(Solon, OH). Total RNA was isolated using the Qiagen RNeasy Mini Kit (Valencia, CA). 
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Template cDNA was obtained by reverse transcription of 4 μg total RNA using the 
Retroscript kit (Life Technologies/Ambion, Grand Island, NY). Real time PCR was 
performed with a BioRad CFX384, and results were calculated using the 2-∆∆Ct method. 
The primers used in this study were as follows: rat Ccnd1 primer, forward 
GCCCTAGCTGCCTACCGACT, reverse ACAGGCTTG GCAATTTTAGGC; rat Ctgf 
primer, forward GCCCTAGCTGCCTACCGACT, reverse ACAGGC 
TTGGCAATTTTAGGC; rat Acta2 primer, forward AGCTCTGGTGTGTGACAATGG, 
reverse GGAGCATCATCACCAGCAAAG; rat Ck7 primer, forward 
AGGAGATCAACCGACGCAC, reverse GTCTCGTGAAGGGTCTTGAGG; human 
CTGF primer, forward AAAAGTGCATCCGTACTCCCA, reverse 
CCGTCGGTACATACTCCACAG.  
 
CHF/ARPKD Patient Liver Tissue Samples  
Paraffin-embedded liver tissue blocks (n=3) and frozen liver tissues (n=5) of 
CHF/ARPKD patient livers were obtained from the KUMC’s Liver Center Tissue Bank, 
PKD Biomarkers and Biomaterials Core at KUMC, the Mayo Clinic (Dr. Peter Harris) 
and Children’s Mercy Hospital, Kansas City, MO. All studies were approved by the IRB 
at the associated institutions. 
 
CWEC Isolation 
CWECs from PCK rats were isolated as described by LaRusso et al. (Muff et al. 
2006). Briefly, biliary tree was obtained by removing hepatocytes after liver perfusion 
with a 37oC collagenase-containing solution. After cutting the biliary tree into small 
 95 
pieces with sterile scissors, the tissue was further digested in 25 ml of MEM medium 
(Corning, Hanover Park, IL) containing 25 mM HEPES (Sigma-Aldrich), 10 mg 
hyaluronidase (Sigma-Aldrich), 8 mg collagenase P (Roche, Indianapolis, IN), and 6 mg 
DNase (Sigma-Aldrich) for 45 min in a 42oC water bath. The tissue pieces were gravity 
sedimented, washed with cold MEM, and resuspended in DMEM/F12 media (Invitrogen, 
Grand Island, NY) supplemented with 1% penicillin-streptomycin (P/S, Invitrogen), 1% 
insulin-transferrin-selenium (ITS, Invitrogen), 10-7 M dexamethasone (Sigma-Aldrich), 
5% fetal bovine serum (FBS, Sigma-Aldrich). The tissue pieces were subsequently 
placed in a 150 mm tissue culture dish and incubated for 2 h at 37oC, then re-
suspended in DMEM/F12 growth medium containing 5% FBS, 1% ITS, 4.11 μg/ml 
forskolin (Sigma-Aldrich), 393 ng/mL dexamethasone, 3.4 μg/ml 3,3’, 5-triiodo-L-
thyronine (Sigma-Aldrich), 1% P/S, 25 ng/ml epidermal growth factor (life Technologies, 
Grand Island, NY), 30 μg/ml bovine pituitary extract (Invitrogen), and poured into a 
tissue culture dish containing collagen gel. After 2 – 3 days of culture, cysts formed from 
proliferating CWECs were digested with collagenase P, trypsinized, and plated on 
collagen-coated plates to form cell monolayers.   
 
Cell Proliferation Assay  
Cell proliferation was measured as described by Yamaguchi et al. (Yamaguchi et 
al. 2006). Briefly, PCK CWECs were seeded in a 96-well culture plate and incubated in 
DMEM/F12 with 1% FBS, ITS, and P/S. After 24 h, the medium was changed to a 
0.002% FBS without ITS. Cells were incubated for another 24 h before the addition of 
0.1, 0.5, 2, and 5 μM verteporfin (VP, a YAP-TEAD interaction inhibitor which prevents 
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YAP-mediated gene transcription) with or without forskolin (a cAMP agonist). After 48 h, 
cell proliferation was determined based on the production of formazan from the CellTiter 
96 Aqueous One Solution Cell Proliferation Assay (Promega). The amount of formazan 
is directly proportional to the number of living cells in the culture.  
 
YAP knockdown in isolated CWECs  
YAP knockdown experiments were conducted in primary liver CWECs isolated 
from PCK rats. Cells were transfected with either control shRNA (sc-108080, Santa 
Cruz Biotechnology) or YAP shRNA (sc-38638-V, Santa Cruz Biotechnology) for 24h. 
Cell proliferation rate was assessed by cell proliferation assay described above. 
Interference efficiency was detected by Western blotting. The ratio of YAP/β-actin was 
quantified with three independent Western blot results using Image J software.  
 
Statistics 
All data are represented as mean ± standard error of mean. Student’s t-test was 
used to calculate differences between two groups. One-way ANOVA was used to 
compare differences in Figure 4.4.7C-D and Figure 4.4.8 A, B, and E. Two-way ANOVA 
was used to compare differences in Figure 4.4.5A. Post-hoc Tukey’s adjustment for 
multiple comparisons was used after each ANOVA. In each case, P<0.05 was 








Extensive proliferation in PCK rat livers.  
Using hematoxylin and eosin (H&E)-stained liver sections from PCK and SD rats, 
we evaluated liver histology from postnatal day (PND) 0 to PND 90. Hematopoietic cells 
(clusters of small cells with basophilic nuclei) were evident in the livers of SD rats on 
PND 0 and PND 5 but were absent at PND 10 (Figure 4.4.1A). This observation is 
consistent with the hematopoietic nature of the perinatal liver (Payushina 2012). The 
portal vein, hepatic artery and bile ducts (the portal triad) were readily identifiable in 
livers from SD rats from PND 10 onward and did not change in appearance through 
PND 90 (Figure 4.4.1A). Similar to SD rats, PCK rat livers contained hematopoietic cells 
at PND 0 and PND 5 but not PND 10 onward (Figure 4.4.1A). Bile ducts were dilated in 
livers from PCK rats from PND 0 onward and the number of cysts developing from 
dilated bile ducts increased throughout the time course, disrupting normal portal triad 
histological structure (Figure 4.4.1A). To determine if there was elevated proliferation of 
CWECs, we stained liver sections from PCK and SD rats with antibodies recognizing 
PCNA (Figure 4.4.1B) and Cyclin D1 (Figure 4.4.1C), markers for cell proliferation. 
Overall, we found more PCNA and Cyclin D1 positive cells in the liver of PCK rats 
compared to that in SD rats, and the PCNA/Cyclin D1 positive cells were not limited to 
CWECs. In order to gain a better insight into CWEC proliferation at mRNA level, we 
measured Ccnd1 transcripts in biliary trees isolated from 6-month-old SD and PCK rats. 
Consistent with immunohistochemistry staining, Ccnd1 mRNA was significantly up-





Figure 4.4.1. Cyst growth and proliferation in PCK rat livers. (A) Representative 
photomicrographs hematoxylin & eosin (H&E) stained livers from SD and PCK rats from 
postnatal day (PND) 0 to PND 90 (3 months). Immunostaining for PCNA (B) and Cyclin 
D1 (C) in SD and PCK rat liver sections. Images were taken at 400X. Arrowheads 
indicate PCNA positive cells (B) or Cyclin D1 positive cells (C). (D) Ccnd1 transcript 
level in biliary trees from 6-month-old SD and PCK rats. N = 4 rats per group. *, P<0.05 
between genotypes. 
 99 
Increased YAP expression in CWECs from PCK rats and Pkhd1LSL(−)/LSL(−) mice.  
Moderate YAP expression was observed in cholangiocytes from SD rat livers 
(Figure 4.4.2A). Higher YAP expression with nuclear localization was observed in the 
CWECs from PCK rats (Figure 4.4.2A-B). In the canonical Hippo signaling pathway, 
phosphorylated YAP is sequestered in the cytoplasm and targeted for degradation (Hao 
et al. 2008). Thus, the ratio of YAP to phospho-YAP is a surrogate marker of YAP 
activity. Immunohistochemistry for phospho-YAP revealed only moderate cytoplasmic 
staining in CWECs from PCK rat livers (Figure 4.4.2B). To further investigate the 
expression of YAP in another model of CHF/ARPKD, we performed YAP staining on 
liver samples from wild type (WT) mice and Pkhd1LSL(−)/LSL(−) mice. Similarly, liver 
samples from Pkhd1LSL(−)/LSL(−) mice exhibited higher YAP nuclear staining in 








Figure 4.4.2. Increased YAP activation in PCK rat livers. (A) Representative 
photomicrographs (400X) of YAP immunohistochemistry in SD and PCK rat livers. (B) 
Representative photomicrographs (600X) of YAP and phospho-YAP 
immunohistochemistry in PCK rat livers. Arrowheads point to cyst wall epithelial cells 
(CWEC) positive for YAP. (C) Representative photomicrographs (400X) of YAP 





YAP is actively expressed in proliferating PCK rat liver CWECs.  
To confirm the association between YAP and CWECs, we performed co-
immunofluorescence (IF) staining for Cytokeratin19 (CK19), a biliary epithelial cell 
marker, and YAP in PCK rat livers. Our co-IF studies showed YAP and CK19 co-
localization in biliary epithelium from SD rats (Figure 4.4.3A); more co-localization of 
YAP and CK19 was observed in CWECs from PCK rat livers (Figure 4.4.3B). These 
data suggest strong association between YAP and CWECs in PCK rats. To test the role 
of YAP in CWEC proliferation, we performed co-IF to determine if YAP co-localizes with 
Ki67 (a cell proliferation marker) in CWECs. As we expected, co-localization occurs only 












Figure 4.4.3. YAP and CK19 co-localization in CWECs. Representative 
photomicrographs of immunofluorescence staining of YAP (red), Cytokeratin 19 (CK19, 
green) and DAPI (blue) on frozen liver sections from SD rats (A) and PCK rats (B). 
Images were taken at 400X. Arrowheads point to co-localization of YAP and CK19.  
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Figure 4.4.4. YAP/Ki67 co-localization is increased in PCK CWECs. Representative 
images of immunofluorescence staining of YAP (red), Ki67 (green), and DAPI (blue) on 
liver sections from SD and PCK rats are shown at 400X. Arrowheads point to co-














CTGF is increased in hepatic cysts in PCK rats.  
YAP regulates expression of connective tissue growth factor (Ctgf), encoding for 
a matricellular protein of the CNN family (Rachfal et al. 2003, Gressner et al. 2008, Pi et 
al. 2008, Zhao et al. 2008, Pi et al. 2015). Real time PCR analysis showed that hepatic 
Ctgf mRNA was greater in livers from PCK rats than in SD rats beginning at PND 10 
(Figure 4.4.5A). Ctgf transcript levels peaked at PND 20 and PND 30 in PCK rats and 
decreased substantially thereafter (Figure 4.4.5A). However, Ctgf mRNA remained 6-
fold higher in the PCK rat livers compared to SD rat livers at 90 days after birth (Figure 
4.4.5B). To determine Ctgf expression level in the absence of hepatocytes, we 
measured its expression in biliary trees isolated from 6-month-old SD rats and PCK rats 
(Figure 4.4.5C). We found Ctgf expression was significantly higher in PCK rat biliary 
trees compared to that in SD rats. Immunohistochemical analysis revealed extensive 
CTGF staining in CWECs from PCK rats compared to SD rats (Figure 4.4.5D). 
Interestingly, CTGF protein was also observed in cells within the pericystic fibrotic tissue 
and hepatocytes (Figure 4.4.5D). Taken together, these data suggest that increased 
YAP content in livers from PCK rats drives the expression of YAP target genes 







Figure 4.4.5.  CTGF expression in livers from PCK rats.  (A) Real time PCR was 
used to quantify hepatic Ctgf transcripts in livers from SD and PCK rats from PND 0 to 
PND 90. N = 3 – 4 rats per time point. (B) Ctgf transcript content in SD and PCK rats on 
PND 90. N = 3 rats in each group. In (A) and (B), filled-in circles indicate SD data while 
filled-in squares indicate PCK data. (C) Ctgf transcript content in biliary trees from 6-
month-old SD and PCK rats. N = 4 rats in each group. (D) Representative CTGF 
immunohistochemistry from PCK rats at PND 90. Images were taken at 400X. 
Arrowheads indicate CTGF-positive cells. *, P<0.05 between genotypes at the given 






Increased YAP, PCNA and CTGF in hepatic cysts in CHF/ARPKD patient samples.  
To determine YAP expression pattern in hepatic cysts in human CHF/ARPKD, 
we performed immunohistochemistry on paraffin-embedded liver sections from two 
CHF/ARPKD patients. Serial sections stained with H&E (Figure 4.4.6A), or with 
antibodies recognizing PCNA (Figure 4.4.6B) or YAP (Figure 4.4.6C and enlarged in 
Figure 4.4.6D), revealed extensive YAP expression with nuclear localization in CWECs, 
which also stained positive for PCNA.  
We also evaluated CTGF content in patient-derived liver samples. We evaluated 
hepatic CTGF transcript levels using real time PCR in 3 normal human liver samples 
and 3 liver samples from patients with CHF/ARPKD. Although, there was variation in 
relative CTGF expression (Figure 4.4.6E), there was a trend towards increased CTGF 
expression in this limited number of samples. An immunohistochemical approach 
revealed substantial CTGF positivity in CWECs as well as in cells found in the pericystic 
fibrotic areas (Figure 4.4.6F and enlarged in Figure 4.4.6G). Collectively, these data 
suggest that, similar to findings in the PCK rat, nuclear YAP content is a prominent 
feature of proliferating CWECs found in CHF/ARPKD patients and is associated with 









Figure 4.4.6.  Characterization of YAP expression, cell proliferation, and CTGF in 
human CHF/ARPKD livers. Representative photomicrographs of H&E stained liver 
sections (A) showing hepatic cysts and surrounding pericystic tissue, and PCNA (B) and 
YAP (C) immunostaining in two different CHF/ARPKD patients. (D) Enlarged image 
(600X) of YAP immunostaining from Patient #2. (E) Real time PCR was used to 
measure hepatic CTGF transcripts in three patients. (F) CTGF immunostaining in one 
CHF/ARPKD patient. The black box outlines the area enlarged in (G). Black arrowheads 
point to CTGF positive CWECs, red arrowheads point to the CTGF positive cells in 





The YAP-TEAD binding disruptor, verteporfin (VP), inhibits CWEC proliferation. 
YAP is not able to bind DNA directly and therefore requires interaction with bona 
fide transcription factors to regulate gene transcription. TEAD (TEA domain family 
member) is a transcription factor and one of the best-characterized binding partners of 
YAP (Vassilev et al. 2001). VP is a chemical inhibitor of the YAP-TEAD interaction and 
prevents YAP-mediated gene regulation(Liu-Chittenden et al. 2012). To explore the role 
of YAP in CWEC proliferation, we examined the ability of VP to inhibit the function of 
YAP in CWEC proliferation, in vitro. We first isolated CWECs from PCK rats and 
characterized them by light microscopy, co-immunofluorescence (co-IF) staining and 
real-time PCR. After isolation, CWECs were cultured, as a monolayer, onto collagen 
gel-coated plates. CWECs formed colonies of cells with a cobblestone pattern 
characteristic of primary epithelial cells in culture (Figure 4.4.7A). To confirm that the 
isolated CWECs still maintained the nuclear staining of YAP, we performed co-IF for 
YAP and CK19 on cultured CWECs. Consistent with co-IF staining in vivo, the PCK 
CWECs stained positive for both YAP and CK19 confirming that these primary cells 
were derived from cholangiocytes, and they maintain the YAP-positive feature in vitro 
(Figure 4.4.7B). This was further confirmed by real time PCR analysis for an additional 
cholangiocyte marker, Ck7. As shown in Figure 4.4.7C, CWECs were enriched for Ck7 
transcripts relative to biliary tree isolated from SD and PCK rats or relative to whole liver 
from SD rats. To exclude the possibility of myofibroblast contamination in our CWEC 
cultures, we quantified Acta2 transcripts (α smooth muscle actin gene) in CWEC 
cultures by real time PCR. CWECs did not express Acta2 while Acta2 was found in 
biliary tree isolated from SD and PCK rats (Figure 4.4.7D) due to fibroblasts found in the 
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connective tissue surrounding the biliary tree. Interestingly, we found the Acta2 level 
was significantly lower in biliary trees from PCK rats. It is possibly due to the increased 
proportion of CWECs in PCK rats compared to the normal cholangiocytes in SD biliary 
tree. Acta2 was not detectable in livers from SD rats (Figure 4.4.7D).  
Next, to determine the role of YAP in aberrant cell proliferation in PCK rats, we 
treated CWECs with various concentrations (0.1, 0.5, 2, and 5 μM) of VP alone or in 
combination with forskolin. Forskolin is a cAMP agonist that stimulates renal cystic 
epithelial cell proliferation in autosomal dominant polycystic kidney disease (ADPKD) 
through activation of the B-Raf-MEK-ERK pathway (Tesmer et al. 1997, Yamaguchi et 
al. 2000). VP treatment alone significantly reduced CWEC proliferation at the dose of 
0.1 μM compared to the DMSO control (Figure 4.4.8A). Furthermore, VP at higher 
doses exhibited greater degree of inhibition on CWEC proliferation. Forskolin treatment 
caused a significant increase in CWEC proliferation, consistent with previous results 
(Francis et al. 2004). Treatment with VP blocked forskolin-mediated CWEC proliferation 
(Figure 4.4.8A). These data suggest that the inhibitory effect of VP on CWEC 
proliferation may occur downstream of a cAMP-mediated pathway. The inhibitory effect 
of VP on YAP-mediated gene expression was confirmed by a significant reduction of 
Birc5 (survivin gene) expression (Figure 4.4.8B). The ability of VP to inhibit CWECs 
proliferation in our model is consistent with the observation that VP can block the 
proliferation in cholangiocyte and cholangiocarcinoma cell lines (Gurda et al. 2014).  
 
YAP knockdown decreases CWEC proliferation. 
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As a second approach to perturb YAP-mediated gene expression, we performed 
a YAP knockdown experiment in isolated CWECs using short-hairpin (sh) RNA. 
Western blot analysis indicated a modest but significant decrease in total YAP protein in 
cells treated with YAP shRNA (Figure 4.4.8C and Figure 4.4.8D). Further, a cell 
proliferation assay indicated a significant decrease in cell proliferation after YAP shRNA 
treatment for 24h (Figure 4.4.8E). Taken together, these data support the hypothesis 
















Figure 4.4.7. Characterization of CWECs isolated from PCK rats. (A) 
Representative phase-contrast micrograph of CWEC growing on collagen gel-coated 
plates as a monolayer (400X). The area demarcated by the white box in the image is 
enlarged in the inset in the bottom right of the same image. (B) Representative 
immunofluorescence image (400X) of CK19 staining in isolated CWECs. Real time PCR 
analysis of Ck7 (cytokeratin 7, a cholangiocyte marker, C) and Acta2 (aSMA, a 
fibroblast marker, D) from SD rat biliary tree (BT), PCK rat BT, PCK CWEC, and SD 








Figure 4.4.8. CWEC proliferation is reduced after inhibition of YAP activity with VP 
and YAP knockdown, in vitro. (A) Effects of different concentrations of verteporfin 
(VP) on cell proliferation. CWECs were treated with the indicated VP concentrations 
with or without forskolin (FSK). DMSO was used as control. (B) Real time PCR analysis 
of Birc5 transcripts after VP treatment. *, significant decrease (P<0.05) relative to the 
DMSO; #, significant decrease (P<0.05) relative to FSK. (C, D) Western blotting 
analysis of total YAP protein after YAP shRNA-mediated knockdown. The YAP band 
intensity was normalized to β-actin. (E) Effect of YAP knockdown on CWEC 
proliferation. Each experiment was repeated three times (CWECs from 3 separate 
biliary trees from 3 separate rats isolated on 3 separate days). The error bars represent 
standard error of mean. *, significant decrease (P<0.05) relative to the no shRNA 
treatment group; #, significant decrease (P<0.05) relative to control shRNA. 
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4.5 DISCUSSION 
CHF/ARPKD is a rare but devastating and progressive genetic disease that is 
especially debilitating in pediatric patients (Turkbey et al. 2009, Wen 2011). Hepatic 
complications due to rapidly developing cysts, accompanied by pericystic fibrosis, 
inflammation and subsequent portal hypertension, lead to significant morbidity and high 
perinatal mortality (Wen 2011). Thirty to forty percent of patients with this disease die in 
the perinatal period (Guay-Woodford 2014). Patients that survive the perinatal period 
require intensive treatment that can include a simultaneous liver and kidney transplant. 
Unfortunately, the mechanisms of hepatic cyst development remain poorly understood, 
which has hindered finding alternative treatment strategies. Although we previously 
hypothesized that a central mechanism regulating CHF/ARPKD is a ‘pathogenic 
triumvirate’ consisting of fibrogenesis, CWEC proliferation and pericystic inflammation 
(Jiang et al. 2016), no specific signaling pathway has been implicated to date in all three 
processes. We propose that one pathway which could regulate all three pathogenic 
processes is the Hippo signaling pathway. For example, previous studies suggest that 
YAP and TAZ (a related transcriptional coactivator) are key activators of fibroblasts, and 
they sustain fibrosis by activating fibroblasts (Liu et al. 2015). As an oncoprotein, YAP 
activation is found in several human cancers (Overholtzer et al. 2006, Zender et al. 
2006, Zhao et al. 2007, Steinhardt et al. 2008), and it plays a key role in the Hippo 
pathway to control cell proliferation in response to cell contact (Zhao et al. 2007). 
Finally, YAP activation promotes endothelial cell proliferation and inflammatory 
response in atherosclerosis (Wang et al. 2016). Therefore, it is logical to predict that the 
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Hippo signaling pathway could be the central pathway regulating each member of the 
pathogenic triumvirate in CHF/ARPKD. 
  A major component of CHF/ARPKD, apart from progressive fibrosis and 
inflammation, is the rapid growth of cysts due to aberrant cell proliferation and fluid 
secretion. Multiple mechanisms are implicated in the regulation of CWEC proliferation 
including calcium and cAMP signaling, the B-Raf/MEK/ERK pathway, VEGF, Cdc25A, 
HDAC6 and Wnt signaling due to LRP5 mutations (Fabris et al. 2006, Gradilone et al. 
2010, Spirli et al. 2010, Masyuk et al. 2012, Spirli et al. 2012, Cnossen et al. 2014, 
Gradilone et al. 2014). Recent studies have highlighted the role of YAP, in the 
regulation of normal and abnormal cell proliferation during postnatal liver growth and 
cancer pathogenesis (Zhou et al. 2009, Lee et al. 2010, Lu et al. 2010, Pan 2010, Song 
et al. 2010, Li et al. 2012, Septer et al. 2012). Interestingly, increased YAP activation is 
also observed in kidney cyst development in ADPKD (Happe et al. 2011). Importantly, 
that study demonstrated increases in renal YAP target genes, Birc3, Ctgf, InhibA and 
Fjx1, a planar cell polarity gene, in Pkd1-deleted mice and in renal tissues from ADPKD 
patients (Happe et al. 2011). Our results are consistent with these studies. However, 
our study is the first to demonstrate that hepatic CWECs have significant YAP over-
expression and activation as demonstrated by increased nuclear YAP localization and 
increased expression of YAP target genes in animals and patients with CHF/ARPKD. 
Therefore, our data suggest that hepatic cystogenesis is associated with deregulation of 
the Hippo signaling pathway. 
In this study, we used PCK rats, a variant of SD rat strain, which harbors a single 
splicing mutation (IVS35-2AàT) in the rat ortholog of human PKHD1, the gene found 
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mutated in human CHF/ARPKD; the PCK rat develops renal and hepatic pathology 
similar to human CHF/ARPKD (Katsuyama et al. 2000, Ward et al. 2002, Masyuk et al. 
2004). We found increased levels of Cyclin D1 and PCNA expression in the CWECs, 
consistent with increased levels of cell proliferation. In addition to CWECs, Cyclin D1 
and PCNA-positive cells were increased in the periportal area of PCK rat livers, 
suggesting that other secreted factors, possibly CTGF, promote the proliferation of 
hepatocytes or other interstitial cells. The mechanisms of hepatocyte proliferation and 
their relation to cyst enlargement are unknown. Previous studies indicated that 
extensive sheer stress in the liver may induce proliferative changes (Schrader et al. 
2011) and it is possible that mechanical stress induced by enlarging cysts may stimulate 
similar changes in hepatocytes. Interestingly, a precedent for YAP/TAZ as 
mechanosensors capable of detecting and responding to the extracellular environment 
has already been established, suggesting that cystogenesis and cyst growth may 
regulate the Hippo signaling pathway in CHF/ARPKD (Low et al. 2014). For example, 
interactions between primary cilia, polycystin (defective in ADPKD), and YAP/TAZ  likely 
occur and function as a mechanosensing system in response to alterations in 
extracellular matrix stiffness (Xiao et al. 2015). Therefore, it is possible that fibrocystin 
deficiency in CHF/ARPKD leads to YAP/TAZ activation by a mechanism involving 
defective primary cilia.  
Our data revealed that CWECs have YAP activation in both PCK rats and in 
CHF/ARPKD patient livers. CWECs in rat and human livers show YAP nuclear 
localization and increased expression of the YAP target gene Ctgf. The increase in Ctgf 
was particularly interesting because of its involvement in ECM synthesis and fibrosis 
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(Gressner et al. 2008, Pi et al. 2015). Ctgf expression was also increased in pericystic 
cells suggesting roles for YAP and CTGF not only in CWEC proliferation but also in 
fibrosis associated with CHF/ARPKD. Interestingly, cross-talk between cholangiocytes 
and myofibroblasts have been suggested by Locatelli et al (Locatelli et al. 2016). By 
secreting chemokines (CXCL1, CXCL10, and CXCL12), cholangiocytes recruit 
macrophages which leads to further macrophage-mediated TGFβ1 activation, resulting 
in hepatic stellate cell activation and collagen accumulation (Locatelli et al. 2016).   
A previous study suggests that VP is an effective inhibitor of the YAP-TEAD 
interaction required for YAP-mediated gene expression and exhibits few side effects 
(Liu-Chittenden et al. 2012). This novel VP function is independent of its current clinical 
application as a photosensitizer in vascular ablation procedures for treatment of some 
ocular diseases, including age-related macular degeneration (2001). VP-mediated 
blockade of the YAP-TEAD interaction does not require photoactivation as it does for its 
use in age-related macular degeneration yet inhibits YAP-induced liver overgrowth in 
vivo and in vitro (Liu-Chittenden et al. 2012). To test the feasibility of targeting YAP-
induced CWEC proliferation as a selective means of inhibiting cyst growth in liver, we 
inhibited YAP-regulated target gene expression with VP, in vitro. We demonstrate here 
that VP effectively decreased CWEC proliferation in the presence and absence of 
forskolin. Our data indicate that the pro-proliferative effect of YAP is possibly functioned 
through cAMP-mediated pathway. The exact molecular mechanisms remain unknown 
and future work is needed to elucidate both the molecular mechanisms of YAP action 
and VP’s efficacy in animal models of CHF/ARPKD.   
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In summary, our data suggest that YAP is an important contributing factor for the 
progression of CHF/ARPKD by promoting the proliferation of CWECs. Our study is 
consistent with what is currently known regarding YAP in renal cyst growth in ADPKD 
(Happe et al. 2011). These data have identified a new potential therapeutic target (YAP) 
and pharmacologic strategy (VP) to reduce disease progression in liver, and possibly 



























CHAPTER V: PRELIMINARY CHARACTERIZATION OF THE 
HYALURONAN NETWORK IN CONGENITAL HEPATIC FIBROSIS IN 




















Autosomal recessive polycystic kidney disease (ARPKD) is a hereditary disease 
that primarily affects the hepatobiliary and renal systems. Congenital hepatic fibrosis 
(CHF) is characterized by hepatic cysts and pericystic fibrosis. Hyaluronan (HA) is a 
polysaccharide composed of repeating D-glucuronic acid and N-acetylglycosamine 
disaccharides of. HA is synthesized at the cell surface by three different hyaluronan 
synthases (HAS) 1, 2, and 3 and can interact with cell surface receptors such as CD44, 
LYVE-1, HARE, TLR2/4, and HA mediated motility receptor (HMMR) to induce a range 
of intracellular signals some of which promote cell proliferation, inflammation, and 
fibrosis. Increased serum HA level and hepatic HA content is observed in liver fibrosis 
caused by various conditions, such as non-alcoholic fatty liver disease, alcoholic liver 
diseases, hepatitis, primary biliary cirrhosis, and hepatocellular carcinoma. But the role 
of HA, HA degrading enzymes, HA binding proteins, and receptors (collectively the ‘HA 
network’) in CHF/ARPKD pathogenesis or progression is unknown. Based on the 
pathogenic roles of the HA network in other human diseases we hypothesized that HA 
contributes to pathogenesis of ARPKD. We observed increased HA accumulation in 
liver samples from polycystic kidney (PCK) rats (an animal model of ARPKD) and 
patients with polycystic liver disease (PLD) compared to controls. In isolated biliary tree 
samples, we found Has1 and Cd44 expression were increased in PCK rats compared to 
Sprague Dawley (SD) rats. Further, transcripts for HA degrading enzymes 
hyaluronidase 1 (Hyal1), Hyal2, Kiaa1199, and transmembrane protein 2 (Tmem2) were 
decreased in PCK rat biliary trees compared to their expression in SD rats. Taken 
together, our data demonstrated that HA level in PCK rats is increased, and this could 
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be due to enhanced synthesis and possibly decreased degradation. Whether HA 
contributes to pathogenesis of CHF/ARPKD remains to be studied.  
5.2 INTRODUCTION 
 
Hyaluronan (HA) is a polysaccharide composed of repeating disaccharides of D-
glucuronic acid and N-acetylglycosamine. It is found in the skin, joint synovium, and eye 
vitreous fluid. As one of the components of peri- and extra- cellular matrix, HA is 
synthesized on the cell surface by one of the three enzymes – HAS1, HAS2, and HAS3 
(Spicer et al. 1998). HA is synthesized and released into the extracellular matrix as a 
high molecular weight (HMW, defined here as ≥500 kDa) polymer (Noble 2002, Ruppert 
et al. 2014). HMW-HA is prevalent in uninjured tissues, and it serves a variety of 
functions aimed at maintaining tissue homeostasis including anti-inflammatory and anti-
angiogenic functions (Rooney et al. 1993, Noble 2002, Liu et al. 2008, Ruppert et al. 
2014). The primary postnatal HA -synthesizing cell types are fibroblasts and endothelial 
cells, and in the liver, activated HSC are the primary source of HA (Vrochides et al. 
1996, Spicer et al. 1998, Jiang et al. 2011, Xu et al. 2013, Neuman et al. 2016).   
HA is degraded by enzymes known as hyaluronidases (Jiang et al. 2011). 
Hyaluronidase (HYAL) 1 and HYAL2 are the most abundant and functionally important 
in the body (Fraser et al. 1997, Csoka et al. 1999, Csoka et al. 2001). HYAL1 is 
expressed in high levels in the liver, kidney, heart and spleen, and located primarily in 
lysosomes within the cell (Csoka et al. 1999, McAtee et al. 2015). Activity of HYAL1 has 
a pH optimum in the range of 4.1-4.3 (Lokeshwar et al. 1999). HYAL2 is ubiquitously 
expressed (Csoka et al. 1999), and its activity at pH 3.8 is optimal (Lepperdinger et al. 
1998). As more research into HA turnover is being done, new HA degrading enzymes 
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are being discovered including KIAA1199 and transmembrane protein 2 (TMEM2) 
(Yoshihara et al. 2013, Yamamoto et al. 2017). Importantly, TMEM2 is likely the long 
sought after extracellular HAase as its pH optimum is 7 (Yamamoto et al. 2017). In 
addition to these specific HAases, reactive oxygen species (ROS) also depolymerize 
HA (Soltes et al. 2006). Previous studies suggest that ROS mediates HA degradation 
by increasing HYAL2 expression and also by directly interacting with HA (Parsons et al. 
2002, Monzon et al. 2010).  
HA interacts with cell surface receptors such as cluster of differentiation 44 
(CD44), LYVE-1, HARE, TLR2/4, and HA mediated motility receptor (HMMR) to induce 
a range of intracellular signals. HA and HA-mediated signaling are implicated in wound 
repair and in many diseases. Patients with advanced liver disease have increased HA 
blood levels, which have a positive correlation to disease severity (Lee et al. 2010, Lee 
et al. 2013, Rostami et al. 2013). Based on these observations, HA is used as a serum 
biomarker of liver disease (Orasan et al. 2016). Increased serum and hepatic HA level 
is observed in liver fibrosis caused by various conditions, such as non-alcoholic fatty 
liver disease (Suzuki et al. 2005), alcoholic liver diseases (Stickel et al. 2003, 
Gudowska et al. 2016), hepatitis C (Guechot et al. 1995, Gudowska et al. 2016), 
primary biliary cirrhosis (Nyberg et al. 1988), and hepatocellular carcinoma (Li et al. 
2016).  
Autosomal recessive polycystic kidney disease (ARPKD) is a genetic disorder 
caused by various mutations in PKHD1 (Ward et al. 2003). Along with renal 
manifestations, affected patients also have dilated bile ductules and biliary-derived 
cysts, with peribiliary fibrosis, termed as congenital hepatic fibrosis (CHF, (Lazaridis et 
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al. 2004)). Although the clinical manifestations of CHF/ARPKD are described, the 
mechanisms behind disease progression remains unknown. Recently, a study using bile 
duct ligated-rats to mimic cholestasis suggests that biliary epithelial cells are the source 
of CD44, and HA-CD44 interaction promotes biliary epithelium proliferation (He et al. 
2008). So far, no studies have been performed to understand the role of HA in 
CHF/ARPKD. Our RNA-seq analysis demonstrates that Cd44 was significantly 
upregulated in PCK rats compared to SD rats from PND 15 to PND 90 (see Chapter II). 
Therefore, we hypothesized that HA may play a role in pathogenesis of CHF/ARPKD, 
and it may regulate cyst growth through interacting with CD44. In our study, we 
investigated the role of HA in the progression of CHF/ARPKD using polycystic kidney 
(PCK) rats as our animal model. Our studies indicate that HA level is increased in 
CHF/ARPKD, and HA accumulation is possibly due to an imbalance between HA 
synthesis and degradation.  
 
5.3 MATERIALS AND METHODS 
Animals and Human Tissue Collection  
Polycystic kidney (PCK, an orthologous model of human ARPKD) rats and 
normal Sprague-Dawley (SD) and were obtained from Charles River Laboratories 
(Kingston, NY). Pkhd1LSL(−)/LSL(−) mice (a mouse model of human ARPKD) were a kind 
gift from Dr. Christopher J. Ward (KUMC). Animal treatment was approved by and 
performed in accordance with the Institutional Animal Care and Use Committee 
(IACUC) at University of Kansas Medical Center (KUMC).  
 123 
For all animals, liver, and plasma were collected for further analysis as previously 
described (Deshpande et al. 2016). Biliary trees from untreated SD and PCK rats were 
also collected for RNA isolation as described previously (Jiang et al. 2017).  
Paraffin-embedded liver sections from patients with polycystic liver disease 
(PLD) were obtained from the KUMC’s Liver Center Tissue Bank. Definition of PLD was 
made based on clinical diagnoses for each patient in the absence of genotype data.  All 
studies were approved by the IRB at KUMC. 
 
RNA isolation, cDNA synthesis and real-time PCR 
Total RNA was isolated from and reverse transcribed into complementary DNA 
(cDNA) as described before (Deshpande et al. 2016). SYBR green (Universal Super 
Mix, BioRad, Hercules, CA) was used for real-time PCR. Results were calculated using 
2−ΔΔCt method. The data were expressed as fold change over controls. 18S was used as 
the housekeeping gene and did not differ between genotypes. Primers utilized in this 
study are found in Table 5.3.1.  
 
Hyaluronan Binding Protein (HABP) Staining  
 Formalin-fixed tissue was cut into 5.0 μM sections before use. Tissue was 
deparaffinized in Safe Clear II and rehydrated in a series of graded ethanols and PBS. 
Endogenous avidin and biotin was blocked (Avidin/Biotin Blocking kit, Vector) for one 
hour. Sections were incubated with normal goat serum at a concentration of 1:67 in 
PBS for 20 minutes followed by an hour incubation with 1mg/mL hyaluronidase (Sigma) 
in 0.9% normal saline for negative controls or 0.9% normal saline. After a brief rinse in 
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PBS, biotinylated-HABP (Calbiochem) at 1:100 in diluted normal goat serum (at a 
concentration of 1:67 in PBS) was applied at room temperature for one hour. To amplify 
the signal, an Avidin/Biotin complex applied for 30 minutes. A second amplification step 
using Tyramide Signal Amplification Plus Fluorescein Evaluation Kit (PerkinElmer Life 
Science, Boston, MA) diluted 1:400 was followed by nuclear staining using DAPI. Three 
to five non-overlapping 100X images were taken for each section using an Olympus 
BX51 microscope with an Olympus BH2RFLT3 burner and Olympus DP71 camera 
operated by DP Controller software (Olympus, Waltham, MA). Each image was taken 
using the same exposure and ImageJ was used to quantify the area and intensity of 
positive staining above a threshold that remained constant for all images.  
 
Sirius Red Staining  
Sirius red staining on liver tissues was performed as previously described 
(McCracken et al. 2016). All images were taken at 100X magnification. Five non-
overlapping images were acquired per liver section. One liver section per mouse/rat in 
each experimental group was photographed. ImageJ was used to quantify the area of 
positive staining and intensity. 
 
Statistics 
 All data are represented as mean ± standard error of mean. Student’s t-test or one-
way ANOVA was used to determine statistical differences. Post-hoc pairwise 
comparisons with multiple testing adjustments were completed using Tukey’s method. 
The comparisons having p-value of less than 0.05 were considered statistically significant.  
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5.4 RESULTS 
Hyaluronan production is increased in PKD.  
We first evaluated HA level by using HA binding protein (HABP) staining on liver 
tissues. As HA is non-immunogenic, we utilized biotinylated HABP that can specifically 
bind to HA and be detected using fluorophore. Using this method, we detected an 
increased HA level in both human PLD patients and in PCK rats compared to their 
respective control (Figure 5.4.1A). To determine which cell population was the major 
source of HA, we isolated total RNA from whole liver, hepatic biliary tree, hepatocytes 
(HC), and nonparenchymal cells (NPC). The purity of isolated biliary trees was 
determined by real-time PCR on Ck7 (a cholangiocyte marker). As illustrated in Figure 
5.4.1B, Ck7 mRNA expressed by PCK rat biliary trees was significantly higher than 
other cell populations from PCK and SD rats. Has1 and CD44 mRNA expression by 
PCK rat biliary trees were also significantly higher than other populations (Figure 
5.4.1C-D). Has2 and Has3 mRNAs were not significantly higher in PCK rat compared to 
that in SD biliary trees (data not shown). 
To investigate how HA level changes as the disease develops, we further 
evaluated HA level by HABP staining using liver sections from SD and PCK rats. We 
selected various time points from PND 10 to PND 90 (Figure 5.4.2). Our data show that 
HA was detected at PND 10 and PND 20 in both SD and PCK rats. At PND 30 and PND 
90, HA level appeared to decrease in both genotypes but remained higher in PCK rats 




Figure 5.4.1. Hyaluronan production is increased in polycystic liver disease (PLD). 
(A) Representative images of biotin-conjugated hyaluronan (HA) binding protein (HABP) 
staining on liver sections from human (a normal and a PLD patient) and rats (a Sprague-
Dawley rat and a PCK rat). The green signal is HABP and DAPI (blue) was used to 
visualize nuclei. (B-D) Real-time PCR was used to quantify Ck7, Has1, and Cd44 
transcripts in whole liver, biliary tree, hepatocytes (HC), and nonparenchymal cells (NPC) 




Figure 5.4.2. Hepatic HA accumulation in SD and PCK rats. Representative images 
of HABP staining used to localize hepatic HA accumulation in SD and PCK rats at PND 




Hyaluronidase expression is decreased in PCK rats.  
Increased HA accumulation in livers from PLD patients and PCK rats could be 
due to increased HA synthesis, reduced degradation, or both. Therefore, we next 
measured expression of 4 hyaluronidases in isolated biliary trees (which contain biliary 
epithelium, and associated liver non-parenchymal cells including myofibroblasts). Our 
data showed that Hyal1 and Hyal2 expression were significantly suppressed in biliary 
tree samples from PCK rats compared to their levels in SD rats (Figure 5.4.3A-B). 
Tmem2, a newly identified cell surface hyaluronidase (Yamamoto et al. 2017), was also 
significantly lower in PCK rats (Figure 5.4.3C). Kiaa1199 transcripts trended lower in 
PCK rats yet did not reach significance (Figure 5.4.3D). Our data suggest that HA 
degradation may be reduced in PCK rats, which could contribute to hepatic HA 






































Figure 5.4.3. Hyaluronidase transcripts in biliary trees from SD and PCK rats. (A). 
Hyal1, (B). Hyal2, (C). Tmem2, and (D) Kiaa1199 transcripts in both genotypes. * 
represents p<0.05 when comparing PCK to SD. N = 4 per genotype.   
 





HA is a major component of ECM in liver fibrosis, and patients with advanced 
liver disease have increased HA blood levels, which have a positive correlation to 
disease severity (Lee et al. 2010, Lee et al. 2013, Rostami et al. 2013). Serum HA level 
is increased in various conditions with liver fibrosis, such as non-alcoholic fatty liver 
disease (Suzuki et al. 2005), alcoholic liver diseases (Stickel et al. 2003, Gudowska et 
al. 2016), hepatitis C (Guechot et al. 1995, Gudowska et al. 2016), primary biliary 
cirrhosis (Nyberg et al. 1988), and hepatocellular carcinoma (Li et al. 2016) and 
therefore, HA is used as a biomarker indicative of liver disease severity. So far, no 
research has examined if serum or hepatic HA increases in CHF/ARPKD. Moreover, no 
studies have examined if HA plays a pathogenic or protective role in CHF/ARPKD or 
other liver diseases. In our study, we showed that HA accumulation was increased in 
liver samples from PCK rats and PLD patients. Transcript levels of HA degrading 
enzymes was reduced in PCK rat biliary trees compared to the SD control.  
Considering what we found in PCK rats and human PLD patients and what is 
known about HA in liver diseases, we hypothesize that HA contributes to the 
pathogenesis of CHF/ARPKD. As HA is synthesized by one of three enzymes (HAS1, 2, 
or 3), our first focus was to investigate if HA synthase expression was increased in PCK 
rats. Our data showed that Has1 expression was increased greatly in biliary trees from 
PCK rats compared to SD rats. Has2 and Has3 expression level were trending to 
increase in PCK rats (data now shown), but the increase in Has2 and Has3 expression 
was not significantly different from SD rats. These data suggest that increased 
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expression of Has1 may contribute to increased synthesis of HA and accumulation in 
CHF/ARPKD. Our study is the first to suggest there is an association between HA levels 
and CHF/ARPKD. 
CD44 is a HA receptor whose biological function in inflammation and tumor cells 
have been investigated comprehensively (Aruffo et al. 1990, Teder et al. 2002, Misra et 
al. 2015). CD44 has many isoforms. These are created through alternative splicing of 
the mRNA and differential glycosylation of the protein. CD44 is responsible for pro-
inflammatory activities, including cell–cell and cell–matrix interactions (Naor et al. 1997, 
Naor et al. 2002, Ponta et al. 2003, Misra et al. 2011). HA-CD44 interaction can activate 
receptor tyrosine kinases (RTKs), and further increased cell survival in several cancer 
cell lines. (Misra et al. 2006). HA-CD44 is also proposed to be crucial in regulating lung 
fibrosis. The ability of activated myofibroblasts to invade basal membrane is partially 
regulated through HA-CD44 interactions and upregulation of HAS1 in the context of 
increased expression of MMPs and inhibitors of MMPs (Li et al. 2011). Similarly, 
Midgley et al. showed that HAS2-dependent production of HA facilitates transforming 
growth factor-β (TGF-β)-dependent fibroblast differentiation through promoting CD44 
interaction with EGFR within membrane-bound lipid rafts. Upon interaction, MAPK/ERK 
and CaMKII are activated, leading to fibroblast differentiation (Midgley et al. 2013).  
CD44 is also implicated in PKD. Recent data suggest that cAMP induces renal 
epithelial cell proliferation and promotes cyst growth by activating Ras-dependent 
PKA/B-Raf/MAPK pathways in CWECs from ARPKD patients (Yamaguchi et al. 2006). 
Interestingly, CD44 variants containing variable exon 6 (v6) have been shown to be 
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important for Ras/MAPK activation, and Ras activation might in turn stimulate CD44 
splicing as a positive feedback loop (Cheng et al. 2006). In addition, an increased level 
of epidermal growth factor receptor (EGF) is found in renal cyst fluid, which is consistent 
with an overexpression of EGF receptor (EGFR) mRNA and protein in renal epithelia in 
cpk mice (Horikoshi et al. 1991). The administration of EGFR tyrosine kinase inhibitor 
does not protect PCK rats from developing renal cysts, possibly due to an increased 
level of cAMP after treatment (Torres et al. 2004). Therefore, we propose that CD44 is 
playing a role in cystogenesis and fibrogenesis through binding to HA in CHF/ARPKD. 
In our study, we observed an increased expression of Cd44 in biliary trees from PCK 
rats compared to SD rats. Since CD44 deficient rats are not commercially available, we 
would like to determine if CD44 is upregulated in mouse models of ARPKD. If so, we 
plan to generate CD44 flox/flox mice to selectively knock out CD44 in the biliary 
epithelial cells in Pkhd1 mutant mice to determine if the loss of CD44 alters the course 
of disease. 
To inhibit HA production, one approach is to create Has deficient mice/rats. 
Has2-/- mice are embryonically lethal due to severe defects in cardiac development 
(Siiskonen et al. 2015). Considering the fact that Has1 transcripts were greatly 
increased in PCK rats, it is plausible to hypothesize that Has1 may contribute disease 
progression more than other Has enzymes. HAS1 expression is transcriptionally 
regulated by TGF-β in synoviocytes (Oguchi et al. 2004, Stuhlmeier et al. 2004) and by 
the pro-inflammatory cytokine interleukin-1β (IL-1β) in fibroblasts (Yamada et al. 2004, 
Uchiyama et al. 2005, van Zeijl et al. 2010). Multiple studies suggest that Has1 is not 
essential for embryogenesis, and Has1 deficient mice are viable and fertile (Kobayashi 
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et al. 2010). Has1 is known as a mediator of inflammation in multiple disease, such as 
atherosclerosis (Marzoll et al. 2009), rheumatoid arthritis (Tanimoto et al. 2001), and 
asthma (Cheng et al. 2011). Further, increased expression of HAS1 is associated with 
many cancers, including ovarian cancer (Yabushita et al. 2004, Yamada et al. 2004), 
colon cancer (Yamada et al. 2004), and multiple myeloma (Adamia et al. 2005). In order 
to investigate the role of Has1 on CHF/ARPKD, further studies are needed to block 
Has1 function by using antibodies, shRNA, siRNA, or other inhibitors s or by creating 
Has1-/- CHF/ARPKD mice/rats.  
In summary, these data indicate that HA level is increased in CHF/ARPKD, and 
this is accompanied by increased expression of Has enzymes and Cd44 in isolated 
biliary trees, and decreased expression of HA degrading enzymes. This suggests that 
increased HA synthesis in the absence of degradation may be responsible for HA 
accumulation in PCK rats. Future work will test the direct effects of the HA network in 





































Autosomal recessive polycystic kidney disease (ARPKD) is a pediatric, ciliary 
disorder. Approximately 30% affected infants die shortly after birth from respiratory 
insufficiency (Zerres et al. 1998). Congenital hepatic fibrosis (CHF), which accompanies 
ARPKD, is a cholangiopathy characterized by biliary ductal plate malformation, which 
leads to progressive hepatic cyst formation and portal fibrosis (Turkbey et al. 2009). 
Previous studies have proposed different mechanisms of cyst growth. Along with cyst 
formation, the mechanisms of cyst expansion are proposed to be the result of: (1) 
cholangiocyte hyperproliferation, (2) cell-matrix interactions, and (3) fluid secretion 
(Gradilone et al. 2010). In Chapter I, we proposed a ‘pathogenic triumvirate’ in 
CHF/ARPKD which includes three factors, cyst growth, fibrosis, and inflammation. Our 
study aims to identify new pathways and central mediators that contribute to the 
pathogenesis by regulating the three components, and develop pharmacological agents 
to target those mediators to manage disease progression. Using RNA-seq analysis 
accompanied by previous studies in cholangiopathies (such as cholestasis), we 
identified three potential regulators of CHF/ARPKD: mast cells, yes-associated protein 
(YAP), and hyaluronan (HA). In this dissertation, we tested our hypothesis that the 
‘Pathogenic Triumvirate’ consisting of proliferation, inflammation, and fibrosis driven by 
interrelated signaling contributes to CHF/ARPKD pathogenesis of CHF/ARPKD.  
 
6.1.1 The role of mast cell in CHF/ARPKD 
Mast cells (MC) are innate immune cells that exhibit pro-inflammatory, pro-fibrotic 
(Overed-Sayer et al. 2013), and growth-promoting activities in rodent models of 
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cholangiopathies (Hargrove et al. 2016, Hargrove et al. 2017). Although our RNA-seq 
analysis didn’t detect any change in MC-related genes in PCK rats when compared to 
SD rats, a previous study shows that MCs surrounded by chymase, a MC granule 
component, were observed in the kidneys from end-stage ADPKD patients (McPherson 
et al. 2004). Moreover, MCs were also found at fibrotic portal tract area in liver samples 
from CHF/ARPKD (Ozaki et al. 2005). Our work using PCK rats demonstrated that MC 
infiltration increased in liver samples from PCK rats compared to Sprague Dawley (SD) 
rats. We provided evidence that MCs were also observed in liver samples from PKD 
patients. We proposed that tryptase was the major granule component that drives 
disease progression based on the observations that: (1) we detected increased 
expressions of tryptase and its receptor protease-activated receptor 2 (PAR2) in 
isolated biliary trees from PCK rats compared to SD rats and (2) serum tryptase level 
was significantly higher in PCK rats compared to SD rats. In humans, serum tryptase 
has become a widely used biomarker in systemic anaphylaxis (Caughey 2006), 
mastocytosis (Sperr et al. 2002), and chronic kidney disease (Sirvent et al. 2010). More 
importantly, tryptase exhibits proliferative action on fibroblasts upon binding to its 
receptor PAR2, which provides insights into the signaling pathway related to the 
interaction between tryptase and fibroblasts that may lead to new therapeutic 
approaches in human fibrotic disorders (Frungieri et al. 2002).  
Contrary to our hypothesis, inhibiting MC degranulation with cromolyn sodium 
(CS, 50mg/kg) or ketotifen (1mg/kg) caused severe cyst growth in livers from PCK rats 
compared to rats given saline (control group). We excluded the off-target effects of CS 
by treating isolated CWECs with CS. Our data suggest that tryptase may function as a 
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protective mediator in hepatic cyst development in CHF/ARPKD. In future experiments,  
we can test our hypothesis by selectively inhibiting tryptase using pharmacological 
strategies. A previous study suggests that inhibiting tryptase activity with a widely 
accepted tryptase inhibitor APC366 inhibits hepatic stellate cell (HSC) proliferation and 
collagen synthesis in a rat model of hepatic fibrosis induced by bile duct ligation (BDL) 
(Lu et al. 2014). Therefore, if tryptase is protective in CHF/ARPKD, we speculate that 
treating PCK rats with APC366 would exacerbate disease progression.  
There is substantial evidence showing that chymase has pro-collagenase 
activity, as it induces the activation of pro- matrix metalloproteinase (MMP2 and pro-
MMP9, in vivo (Tchougounova et al. 2005). Chymase exhibits protective effects on renal 
tubulointerstitial fibrosis through decreasing inflammatory cell infiltrate and degrading 
interstitial deposits of fibronectin (Beghdadi et al. 2013). Consistently, the absence 
of MCs strikingly exacerbates hyperhomocysteinemia-induced adverse cardiac 
remodeling and diastolic dysfunction, indicating a potential protective role for MCs in 
cardiac injury (Joseph et al. 2005). On the other hand, chymase aggravates bleomycin-
induced pulmonary fibrosis by digesting latent transforming growth factor-β1 (TGF-β1) 
to its active form. The chymase inhibitor SUN C8077 reduces collagen accumulation in 
the lung by blocking TGF-β1 activation and collagen synthesis in this model (Tomimori 
et al. 2003). It is possible that different MC granule components may have different 
roles in CHF/ARPKD, which depends on type of organ and the type of disease. The 
effects of MCs on disease progression may also depend on factors such as the kinetics 
of fibrosis development and the organ affected.  
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In trying to understand which MC granule component may be protective in 
CHF/ARPKD, one next step could be to treat isolated hepatic CWECs with individual 
MC granule components and measure cell proliferation change. Furthermore, it is likely 
that deficiency of PKHD1 expression in CHF/ARPKD causes a differential response to 
MCs. It would be plausible to test the response to MC granule components in normal 
cholangiocytes from SD rats. In addition to observing an exacerbated effect on hepatic 
cyst growth after CS treatment, we noticed that renal cyst size was decreased by CS. 
Our study reveals that there might be an organ specific effects of MCs that may in part 
be determined by the disease stage and the pathological environment. To further 
investigate the effects of MCs on renal cyst growth, treating isolated renal cystic 
epithelial cells with isolated MC granules, and comparing the response to that of normal 
renal epithelial cells will provide evidence for our hypothesis. In particular, we would like 
to test the effect of renin, one of the MC granule components, on renal epithelial cell 
proliferation. Previous studies suggest that renin-angiotensin system (RAS) is 
upregulated in liver and kidney samples from PCK rats (Goto et al. 2010, Goto et al. 
2010). In ADPKD, RAS activation contributes the progression of disease not only 
through promoting hypertension, but also by stimulating renal cyst growth (Torres et al. 
2012). In order to achieve therapeutic effects on both liver and kidneys, it is imperative 
to target the specific MC granule component that has similar effects on both organs 
instead of inhibiting MC degranulation.  
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6.1.2 The role of YAP in CHF/ARPKD 
Our work revealed that YAP was activated in liver samples from PCK rats and 
PKD patients, and that preventing YAP function with Verteporfin can inhibit hepatic cyst 
wall epithelial cell (CWEC) proliferation. Verteporfin is a YAP-TEAD interaction inhibitor, 
and it leads to cytoplasmic YAP sequestration through increasing the levels of 14-3-3σ, 
a YAP chaperon protein. By increasing 14-3-3σ level, Verteporfin prevents YAP 
translocation from nucleus to cytoplasm. (Wang et al. 2016). Interestingly, p53 is 
required for 14-3-3σ to effectively retain YAP in the cytoplasm and target it for 
degradation by the proteasome (Wang et al. 2016). In vivo, Verteporfin exhibited a 
significant inhibitory effect on tumor growth in a mouse model of ovarian cancer (Feng 
et al. 2016). Similarly, Verteporfin can suppress hepatomegaly/tumorigenesis resulting 
from YAP overexpression (Liu-Chittenden et al. 2012). In our study, we injected PCK 
rats and Pkhd1LSL/LSL mice with Verteporfin (90 mg/kg) three times per week for two 
weeks to investigate the in vivo efficacy of Verteporfin, but we did not observe any 
beneficial impact on hepatic cyst growth or fibrosis (data not shown). We also noticed 
that Verteporfin was not fully absorbed by animals suggesting solubility issues 
prevented the expected therapeutic effect. Verteporfin was initially dissolved in DMSO, 
and diluted to desired concentration. Thus, we propose to dissolve Verteporfin in a 
different solvent or a different percentage of DMSO to achieve better solubility and 
therapeutic efficacy.  
In this study, we provided evidence that YAP is a critical mediator of 
CHF/ARPKD, and it drives disease progression by regulating downstream target gene 
expression (CTGF, CCND1,). In addition to pharmacologically inhibiting YAP activity, 
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we also genetically deleted YAP in CWECs from PCK rat livers using YAP-targeting 
shRNA. Although we only achieved 50% reduction in YAP, we demonstrated an 
inhibition of CWEC proliferation. Consistently, epigenetic regulation of YAP by 
microRNA-375 also suppresses YAP protein in primary hepatocellular carcinoma cell 
lines (Liu et al. 2010). Thus, miR-375 could be used with YAP shRNA in our animal 
models to increase YAP inhibition, and further attenuate CHF/ARPKD progression. 
Furthermore, we would like to investigate upstream regulators of YAP, such as large 
tumor suppressor homolog 1/2 (Lats1/2) and Mammalian sterile 20-like kinase 1/2 
(Mst1/2), in PCK rats and in ARPKD patients. A previous study shows that Lats1/2 
phosphorylates YAP and results in YAP inactivation via Ser-127 phosphorylation-
mediated spatial regulation and Ser-381 phosphorylation-mediated temporal regulation 
(Zhao et al. 2010). More importantly, Lats1/2 kinases regulate the development of liver 
progenitor cell differentiation and maturation in hepatocytes and biliary epithelial cells 
through regulating activation of YAP/ TAZ (transcriptional coactivator with a PDZ-
binding domain, (Yi et al. 2016). Thus, it is plausible to hypothesize that Lats1/2 activity 
is reduced in CHF/ARPKD. Deletion of Lats1/2 in CHF/ARPKD should abolish the 
phosphorylation effect of YAP/TAZ, leading to hyperactivation of YAP and detrimental 
effects on disease progression. 
 
6.1.3 Is there a role for hyaluronan dysregulation in CHF/ARPKD? 
CD44-HA interactions could drive each component of the ‘pathogenic 
triumvirate’. For example, in a rat model of cholestasis, biliary epithelial cells (BEC) are 
the major source of CD44, and HA treatment stimulates BEC proliferation (He et al. 
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2008). Therefore, we hypothesize that HA-CD44 interaction may stimulate CHF/ARPKD 
progression through regulating CWEC proliferation. Additionally, CD44-HA interactions 
can exacerbate inflammation. For example, expressed on the majority of immune cells, 
CD44 contributes a variety of inflammatory diseases including inflammatory bowel 
disease (Wittig et al. 1999), collagen- and proteoglycan-induced arthritis (Zeidler et al. 
1995), and inflammatory colitis (Wittig et al. 2000). Therefore, it is reasonable to 
hypothesize that HA-CD44 interaction drives inflammation in CHF/ARPKD. Finally, HA-
CD44 drives fibrosis. CD44 promotes lung fibrosis by interacting with HA and, as a 
consequence, upregulates HAS2, an HA synthase. HA-CD44 interaction and 
upregulation of HAS2 promote fibroblast invasion and lung fibrosis. Consistently, 
blocking CD44 with a neutralizing antibody reduces lung fibrosis in mice in vivo (Li et al. 
2011).   
Using our data regarding Cd44 transcripts in livers from PCK rats and published 
literature as a solid foundation, we sought to further characterize on the HA network (HA 
and associated biosynthetic/degrading enzymes, receptors, and binding proteins) in 
CHF/ARPKD. We found that hepatic HA content was increased in PCK rats.  
Consistently, transcript analysis for hyaluronan synthases and hyaluronan degrading 
enzymes suggests that HA synthesis is increased and HA degradation is suppressed in 
PCK rats. Previous studies suggest that inhibiting HA synthesis can inhibit diseases. 
For example, a chow diet containing 5% 4-Methylumbelliferone (4-MU) effectively 
inhibits serum HA level at day 7 and prevents disease in a mouse model of 
experimental autoimmune encephalomyelitis (EAE) and autoimmune diabetes (Kuipers 
et al. 2016). More importantly, 4-MU treatment suppresses HSC activation and liver 
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fibrosis in a rat model of cholestasis (Sawada et al. 2016). In vivo, oral dosage of 4-MU 
is rapidly metabolized by conjugating to either a glucuronic acid to form 4-MU 
glucuronide (4-MUG) or a sulphate, forming 4-MU sulphate (4-MUS) within 24h (Kuipers 
et al. 2016). Interestingly, oral but not i.p. dosage of 4-MU inhibits HA synthesis and 
shows therapeutic effects in autoimmune diseases in mice, suggesting uptake of 4-MU 
through the gut contributes to its therapeutic efficacy (Kuipers et al. 2016). The direct 
connection between the gut and the liver provides strong rationale for the therapeutic 
efficacy of 4-MU in models of liver disease such as the study by Kuipers et al. (Kuipers 
et al. 2016). Together, these data suggest that HA-CD44 interaction can be pathogenic 
in the progression of CHF/ARPKD, and inhibition of HA synthesis with 4-MU may have 
beneficial effects.  
In future studies, we plan to inhibit HA synthesis, and we also propose to 
interrupt HA-CD44 interaction by using a CD44-neutralizingantibody. Previously 
published work suggests that incubation of cultured fibroblasts with anti-CD44 
monoclonal antibodies induces fibroblast apoptosis within fibrin matrices (Henke et al. 
1996). We observed increased Cd44 expression in isolated biliary trees from PCK rats 
compared to SD rats. Considering that biliary trees are composed of CWECs and 
attached myofibroblasts, we speculate that both of them may express Cd44. If so, 
blocking CD44 function may show beneficial effects by inducing fibroblast apoptosis, 
and inhibiting CWEC proliferation. By targeting two components of the ‘pathogenic 
triumvirate’, we expect that blocking CD44 activity can have beneficial effects on 
CHF/ARPKD. Alternatively, we can breed CD44-deficient mice with mouse models of 
CHF/ARPKD, and test how does this affect the pathogenesis of the disease.  
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6.1.4 RNA-seq analysis identified several potential mediators in CHF/ARPKD 
Our RNA-seq analysis showed that members of STAT family were activated in 
PCK rats, such as STAT1, STAT3, STAT4, and STAT5B. STATs are proteins that can 
regulate gene transcription after activated by phosphorylation on tyrosine (Darnell et al. 
1994). Recent work has revealed that polycystin 1 can regulate the transcription factor 
STAT3, and that STAT3 is aberrantly activated by tyrosine-phosphorylation in the kidneys 
of ADPKD patients and PKD mouse models (Talbot et al. 2011, Weimbs et al. 2013). The 
membrane anchored PC-1 activates STAT3 in JAK2-dependent manner, but the cleaved 
tail of PC-1 can only coactivate STAT3 in a mechanism requiring STAT phosphorylation 
by cytokines or growth factors (Talbot et al. 2011). Inhibition STAT3 activation with 
curcumin reduced proliferation index, cystic index, and kidney weight/body weight ratios 
in a mouse model of ADPKD. In addition, renal failure was significantly postponed in the 
study (Leonhard et al. 2011). In PCK rats, STAT3 was predicted to be activated at PND 
30 and PND 90 by our RNA-seq analysis. Therefore, we propose to inhibit STAT3 or its 
upstream regulator JAK2 in PCK rats from PND 30, which also coincides with the rapid 
increase of hepatic cysts. In addition to curcumin, S3I-201 has been synthesized as a 
selective STAT3 inhibitor to treat tumors. It preferentially inhibits STAT3 DNA-binding 
activity and diminishes STAT3 tyrosine phosphorylation (Siddiquee et al. 2007). During 
skin tumor development, STAT3 functions as an anti-apoptotic molecule during tumor 
initiation, and it functions as a regulator of cell proliferation and survival during tumor 
promotion (Chan et al. 2004). SAR317461, a JAK2 specific inhibitor, inhibits STAT3 
phosphorylation and has substantial activity against stem cells from glioblastoma 
multiforme (Mukthavaram et al. 2015). We speculate that inhibiting STAT3 activity in PCK 
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rats should exhibit therapeutic effects by decreasing hepato-/renal- CWEC proliferation 
and by increasing CWEC apoptosis.  
 
Investigate the role of HNF4α in CHF/ARPKD 
Hepatocyte-nuclear-factor 4-alpha (HNF4α) is a nuclear receptor that is associated 
with transcriptional regulation of hepatocyte genes involved in lipid metabolism, 
gluconeogenesis, bile acid synthesis, conjugation and transport (Hayhurst et al. 2001, 
Rhee et al. 2003, Inoue et al. 2004). HNF4α is important for morphological and functional 
differentiation of hepatocytes (Hang et al. 2017), and is the dominant regulator of the 
epithelial phenotype for normal liver architecture (Parviz et al. 2003). Our IPA analysis 
suggested that HNF4α was inhibited in PCK rats at PND 30 and PND 90. Inhibition of 
HNF4α is likely to cause impairment in hepatocyte development and function. Full body 
knockout of HNF4α is embryonic lethal, and the liver-specific albumin promoter-driven 
Cre recombinase knockout mice display severe hepatic metabolic disruption and death 
at 6–8 weeks of age (Chen et al. 1994, Hayhurst et al. 2001). The role of HNF4α has not 
been investigated in ARPKD so far. Interestingly, mice double mutants for Pkd1 and 
HNF4α had a worsened phenotype, suggesting that HNF4α may play a role in 
cystogenesis (Menezes et al. 2012). The role of HNF4α in ARPKD can be tested by 
activating HNF4α in PCK rats or mouse models of ARPKD either genetically or 
pharmacologically. In vitro, overexpressing HNF4α in isolated hepatic CWECs with 
doxycycline (Dox)-inducible HNF4α using lentiviral vectors should have inhibitory effect 
on CWEC proliferation.  
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Study the role of TGF-b1 in CHF/ARPKD 
Transforming growth factor-b1 (TGF-b1) is a pro-fibrotic cytokine that exerts its 
effects by activating downstream SMAD signaling (Wrana et al. 1994). TGF-b1 plays 
pathogenic roles in fibrosis by three possible mechanisms: (1) TGF-b1 promotes 
production of ECM through SMAD3- dependent- and independent- mechanisms 
(Samarakoon et al. 2012); (2) TGF-b1 inhibits ECM degradation by inhibiting MMPs but 
inducing TIMPs (tissue inhibitor of metalloproteinase) (Kwak et al. 2006); (3) TGF-b1 
plays a critical role in transdifferentiation toward myofibroblast from different cell types 
(Wu et al. 2013). SMAD7 is an inhibitory effector of TGF-b/SMAD signaling. Our RNA-
seq analysis suggests that SMAD7 was inhibited in PCK rats at PND 30 and PND 90. We 
found that TGF-b level was significantly increased in biliary tree samples from PCK rats 
compared to SD rats (data not shown). Therefore, we propose that TGFb/SMAD signaling 
can be a therapeutic target in CHF/ARPKD. TGF-b inhibitors have been tested in 
preclinical and clinical trials. In the future, studies using different TGF-b inhibitors could 
be tested in PCK rats.  
 
6.2 CONCLUSIONS 
The studies outlined in this dissertation provide insight into novel mechanisms in 
progression of CHF/ARPKD. So far, the treatment options for CHF/ARPKD are limited. 
Our work revealed that the disease is regulated by the ‘pathogenic triumvirate’ including 
cyst growth, fibrosis, and inflammation. Our studies identified several mediators, such 
as YAP, mast cells, and HA that may regulate the ‘pathogenic triumvirate’, some of 
which were surprising and worthy of further study. We also analyzed the disease at 
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transcriptional level by performing RNA-seq analysis. We uncovered several potential 
mediators such as STATs, HNF4α, and TGF-b/SMAD signaling that can be tested in 































Figure 6.2.1. Current working model describing the role of the ‘pathogenic 
triumvirate’ and its mediators in CHF/ARPKD. We proposed that there is a 
‘pathogenic triumvirate’ in CHF/ARPKD that is composed of cyst growth, inflammation, 
and fibrosis. In this dissertation, we described the role of mast cells, YAP, and 
hyaluronan in CHF/ARPKD pathogenesis. We also proposed several other mediators 
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